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Cancers arise from unregulated cellular growth and exhibits a range
of pathophysiological characteristics and behaviour. The term
“tumour heterogeneity” encompasses a broad range of tumour fea-
tures that have arisen as a result of different mechanistic processes
including stem-cell origin, tumour evolution (linked to genetic
mutations and adverse tumour microenvironment) and clonal re-
sistance (as a consequence of treatment). Tumour heterogeneity
may be intra-tumoural (i.e. within the same tumour), inter-
tumoural (i.e. between lesions in the same patient) and inter-
individual (i.e. between patients).
The understanding of tumour heterogeneity is important because it
is a barrier to curing cancers; and improved understanding can lead
to better individualised treatments. Tumour heterogeneity is linked
to treatment resistance and the emergence of aggressive tumour
phenotypes. There is thus a need for biomarkers to identify relevant
tumour sub-clones to which specific therapies may be directed.
Current approaches to enhance our understanding of tumour hetero-
geneity include genomics analysis using either multi-tumoural region
and/or longitudinal tumor tissue sampling. However, non-invasive
imaging using CT, MRI and PET imaging can provide an overview of
the imaging characteristics of multiple disease sites across the body,
thereby provide critical information about intra- and inter-tumour
heterogeneity.
Using functional and molecular imaging techniques, imaging can be
used to quantitatively measure different aspects of tumour biology;
thus identifying imaging phenotypes linked to different stem-cell
origins, gene expression, tumour evolution, treatment efficacy (in-
cluding differential treatment response) and the emergence of clonal
resistance. The emerging evidence for the use of imaging to explore
and understand tumour heterogeneity will be presented and
discussed.
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biology of childhood tumors over the past several decades have led
to improved patient survival. In 2009, the U.S. population of child-
hood cancer survivors was estimated at one in 570 young adults
aged 20 to 34 years [1]. This rapidly growing population underscores
the importance of studying long-term complications of cancer ther-
apy. While childhood cancer patients are returning to the main-
stream of life, toxicities from prior therapy may compound or
potentiate changes typically seen with the normal aging process.
Physical consequences of disease and therapy (e.g., surgery, chemo-
therapy and radiation therapy) such as scoliosis, craniofacial dyspla-
sia, and limb-length discrepancy, may present functional limitations,
psychosocial challenges, and require extensive surgical interventions.
However, skeletal toxicities [2] such as osteonecrosis [3-5] and defi-
cits in bone mineral density [6, 7] are typically silent until they reach
advanced stages when attempts at amelioration may be unsuccess-
ful. These two sequelae result from multifactorial interactions includ-
ing genetic predisposition, disease, therapy (chemotherapy and
radiation therapy) and physical activity. As both bone mineral density
deficits and osteonecrosis may occur in a single patient, therapeutic
interventions may be complex and standard treatment practices for
one of these sequel may exacerbate the other toxicity.
Osteonecrosis is an important long-term toxicity that can comprom-
ise joint functionality and, thus, quality of life in survivors of child-
hood cancer in whom it develops. Its development is multi-factorial
but understanding of this process in pediatric oncology is complex
and incomplete. Osteonecrosis affects up to one-third of pediatric
leukemia patients and is typically asymptomatic in its early stage
when most susceptible to treatment [3]. Despite this fact, it is only
when pain occurs that osteonecrosis is typically suspected. MR im-
aging is the diagnostic modality of choice for screening, follow-up
and risk prediction of functional deterioration in early stages and
readily demonstrates osteonecrotic parameters such as size of the le-
sion, involvement of articular surface, presence of a crescent sign,
etc. Clinical symptoms and demographics are predictive of disease
progression in pediatric steroid-induced hip osteonecrosis [3].
This presentation will concentrate on what is known, factors as yet
unknown, and potential implications of such toxicity. It will focus on
bone mineral density deficits which may predispose childhood can-
cer survivors to earlier onset and more severe osteopenia and
osteoporosis than the normal population. Also detailed, will be osteo-
necrosis which predisposes survivors to impairment of joint function.
Therapeutic interventions for osteonecrosis are currently limited
and ultimately, may lead to joint resurfacing or replacement at a
young age.
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The treatment of both early and late stage breast cancer has evolved
markedly over the past three decades, hence the significant reduc-
tion in breast cancer mortality observed in developed countries over
the past three decades [1]. However, the majority of breast cancers
are still treated with a combination of surgery and radiotherapy, gen-
erally with some form of axillary procedure. Thus, the commonest
locoregional effects of breast cancer treatment are secondary to sur-
gery and to a lesser extent, radiotherapy.
Surgical effects can be acute or chronic. Acute effects include post-
operative seromas, haematomas, and infection. Postoperative
seromas are extremely common and can persist for years [2].
Occasionally they may be very uncomfortable, especially in the axilla,
necessitating ultrasound-guided aspiration, often repeated. Rare con-
sequences of autologous reconstructions secondary to inadequate
tissue perfusion include wound breakdown and necrosis, but in the
chronic phase, the commonest complication of surgery by far is fat
necrosis, which can present with a symptomatic lump. Though the
imaging appearances of mature fat necrosis are characteristic, it can
cause diagnostic confusion initially, with solid-appearing masses on
mammography, ultrasound and MRI, and indeterminate or suspicious
mammographic microcalcification [3]. Together with the less com-
mon epidermal inclusion cysts, the major issue with these benign
complications is the resultant patient anxiety, since the main differ-
ential diagnosis is obviously local recurrence [4]. However, post-
surgical complications tend to occur earlier than recurrent disease
and the imaging differentiation is usually straightforward.
The short-term effects of whole breast radiotherapy are predictable,
with radiation-induced oedema, skin and trabecular thickening,
which is readily apparent at mammography and ultrasound. Such
changes peak around 18 months post radiotherapy and then
generally diminish. However, patients may be symptomatic with ten-
derness and focal thickening for years after radiotherapy. The longer-
term effects are less predictable, particularly the development ofradiation induced angiosarcoma [5]. The latency for this condition
ranges from 3 to 20 years but with breast cancer increasingly becom-
ing a chronic disease, it is likely that it will be seen more often. The
other devastating effect of radiation to the axilla and supraclavicular
fossa is radiation induced brachial plexopathy [6]. This highly debili-
tating iatrogenic complication is mercifully much less common with
modern conformal radiotherapy techniques and careful observance
of fields and dosages. Nonetheless the differentiation between radi-
ation induced and malignant plexopathy can be challenging and
may necessitate MRI and PET scanning [7, 8].
Recognition of the long-term sequelae of conventional treatment of
breast cancer has resulted in a move towards more breast conserva-
tion, (with oncoplastic surgical techniques if necessary), less axillary
intervention (with less resultant lymphoedema) and accelerated par-
tial breast irradiation techniques. These all result in specific imaging
findings on surveillance mammography which the breast radiologist
needs to be aware of, for example more frequent fat necrosis at the
site of the surgical excision after intra-operative radiotherapy [9]. Fi-
nally, it is important for the general cross-sectional radiologist to be
aware of the spectrum of normal imaging findings at CT after com-
plex reconstructive surgery and to recognise when a finding needs
further evaluation [10].
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Cancer therapy-induced CNS toxicity comprises a wide spectrum of
clinical and radiological complications, causing significant morbidity
and mortality [1].
Adequate interpretation of the neuroimaging findings of patients ex-
periencing neurotoxicity represents a complex diagnostic challenge
and requires a detailed knowledge of the underlying pathology
(systemic disease or CNS tumour), of the treatment protocol and
schedule used, and of the timing of symptoms’ onset.
Early recognition of toxic injury is fundamental to discontinue
the offending agent, to judge the overall success and efficacy
of therapy and to institute early treatment of neurotoxic com-
plications [2].
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determine acute and delayed brain side effects [3].
CT induced toxicity can be caused by several drugs and among dif-
ferent patterns of injury the most common presentations include
Posterior Reversible Encephalopathy Syndrome and Acute Toxic Leu-
koencephalopathy [4].
Among RT induced complications “pseudoprogression” and radiation
necrosis are respectively early and late delayed effects, enhanced by
concomitant CT, that can be associated with clinical worsening mim-
icking disease progression [5,6].
Late delayed RT induced complications include also diffuse radiation
leukoencephalopathy, cavernous malformations, mineralizing micro-
angiopathy and pituitary disfunction, which are extremely common
in the paediatric population [7].
Conventional Magnetic Resonance Imaging (MRI) with current high
field systems is the gold standard method for the evaluation of ther-
apy related brain alterations. Advanced imaging modalities such as,
Diffusion Weighted Imaging, Magnetic Resonance Spectroscopy and
Perfusion Weighted Imaging, as well as Positron Emission Tomog-
raphy with amino-acid tracers, may substantially improve the ability
to orient a proper diagnosis and to guide patient management.
When MRI is unavailable or contraindicated, Computerized Tomog-
raphy (CT) remains an alternative diagnostic tool, even though its
role in acute settings is mainly limited to rule out haemorrhage.
Evaluation and depiction of the most common neuroimaging pat-
terns of brain injury induced by cancer therapy is the focus of the
present work.
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The most compelling evidence supporting the use of low dose com-
puted tomography in the screening of high risk populations for lung
cancer was generated by the National Lung Cancer Screening Trial
carried out in the United States by the National Cancer Institute and
the American College of Radiology Imaging Network. This trial was a
randomised prospective study which included over 53,000 partici-
pants. Data from the NLST demonstrated that screening reduced
mortality by 20 % in the CT arm [1]. Other smaller studies carried out
in Europe have reported no mortality benefit. However, these studies
included a younger screening population, had a smaller number of
participants and probably did not have the power to show amortality benefit. Major medical societies and US government agen-
cies such as US Preventative Services Task Force and the Center for
Medicare Services have now recommended LDCT. These decisions
not only recommend screening but require US insurance companies
and Medicare in the US to provide reimbursement.
In the United States, the Center for Medicare and Medicaid Services
(CMS) decision to provide reimbursement for lung cancer screening
with low dose CT included a number of specific criteria for the estab-
lishment of lung cancer screening programs [2]. It requires a written
order from a physician for the initial and subsequent screens and a
required office visit with the referring physician in which the patient
would be counseled concerning lung cancer screening and a shared
decision making would be implemented. Also included are criteria
for radiologist eligibility including certification by the American Board
of Radiology or equivalent and the interpretation of at least 300
chest CTs in the past 3 years and documentation of continuing med-
ical education. Radiology imaging centers must be accredited as well.
The American College of Radiology is providing such accreditation.
CMS is also requiring collection and submission of data by an ap-
proved national registry for each screen performed.
The American College of Radiology has developed a reporting system
for lung cancer screening designated “Lung Rads” [3]. It is very similar
to Bi-Rads that includes numeric categories. It associates CT findings
with guideline based management decisions. LDCT findings are catego-
rized from 1-4 according to the likelihood of malignancy. 1 and 2 are
considered benign findings and 3 and 4 have a higher probability of
malignancy. There are descriptions for each of the 4 categories plus an
enumeration of findings. The categories include characterization of
nodules including size and density (solid, part-solid, or non- solid
ground glass). In addition to the categories and findings there are
guidelines for management in each category with estimates of the
probability of malignancy and the estimated population prevalence.
Some of the caveats of screening result from the limits of
generalization of the NLST results based on risk groups and demo-
graphics. There are also potential harms and complications from the
LDCT screening which include radiation exposure, overdiagnosis/
overmanagement, the use of invasive procedures for diagnosis and
the high false positive rate [4]. Nevertheless, these potential limita-
tions, harms and complications seem to be outweighted by the ben-
efits of screening.
In the future, we will see a consolidation of the body of evidence
and gain new insights through the pooling of the European trial data
(Nelson [5]), and the UK Lung Cancer Screening trial pilot study [6].
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Risk stratification is important for large and small nodules. Special is-
sues arise with small pulmonary nodules defined as less than 8 mm.
The vast majority of these are benign.
There are both clinical and imaging risk factors for malignancy that
should be taken into account. Clinical risk factors include older age, his-
tory of smoking, history of extrathoracic cancer within 5 years, and fam-
ily history of cancer. The CT characteristics that indicate risk from
malignancy include a size of greater than 8 mm, certain border charac-
teristics, density features, growth, and location. A presumptive benign
diagnosis can be made on the basis of 2 year stability excluding ground
glass nodules which require longer follow-up. Benign calcification (dif-
fuse, central, laminated, and popcorn), the presence of fat, a size less
than 4 mm and perifissural location are very strong predictors of benig-
nity and no further evaluation of such nodules is required.
Adequate evaluation of solitary pulmonary nodules requires thin sec-
tion CT with a 1.5 to 2 mm slice thickness.
The solidity of nodules is important in determining their malignant po-
tential. Among purely solid nodules, a size greater than 8 mm, location
in the upper lobes, spiculated or lobulated contour, and internal charac-
teristics such as eccentric calcification, air bronchograms and cavitation
are helpful predictors of malignancy in addition to the growth rate.
Small nodules less than 4 mm have less than a 0.5 % chance of malig-
nancy even in smokers. Nodules in the range of 8-10 mm or greater
have a 10-20 % chance of malignancy. The management of small solid
nodules less than 8 mm often consists of imaging follow-up according
to current recommendations by the Fleischner Society.
Subsolid nodules represent the spectrum of peripheral adenocarcin-
omas of the lung and may be mixed part solid/part ground glass or
pure ground glass nodules. Part solid nodules have the highest
likelihood of malignancy in the range of 60 to 70 %. Malignancy in
subsolid nodules is associated both with lesion growth and the de-
velopment and growth of the solid component.
In summary, small solitary pulmonary nodules commonly detected on
CT are mostly benign. It is imperative that clinical risk factors which are
mostly socio-demographic be evaluated. Important imaging findings in
determining the risk of malignancy includes size, location, morphology
and classic benign features, growth rate, and solidity.
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Over the past 2 decades, positron emission tomography with the
tracer [18F]fluorodeoxyglucose (FDG-PET) has gained increasing utility
and importance in the diagnosis and management of patients with
pulmonary nodules that may represent non-small cell lung cancer
(NSCLC) [1]. It is evident that FDG-PET does not replace the need for
pathologic examination, but contributes to decisions about when to
obtain tissue and from what location(s). Studies have shownrepeatedly that overall patient survival and progression-free survival
in NSCLC are predicted by the lesion intensity in FDG-PET at initial
characterization [2-4]. Thus, although many non-neoplastic lesions
can be FDG-avid, and while many instances of low-grade malignancy
may be FDG “negative”, use of serial anatomic imaging in the latter
patients may suffice to characterize lesions, without significant risk of
upstaging when malignancy is found in a growing lesion. Presence
of avid FDG uptake in a new pulmonary lesion identifies cases where
tissue diagnosis should be expedited, and may serve simultaneously
to stage the malignancy. More recent evidence suggests an added
role of FDG-PET in directing needle biopsy of pulmonary lesions, im-
proving diagnostic yield [5].
An emerging application of FDG-PET in NSCLC is in the assessment
of therapeutic response [6], and in the possibility of applying indivi-
dualised, adaptive therapy. Studies in the use of external beam radio-
therapy have identified predictive value of initial FDG activity
patterns in NSCLC lesion(s) with the likelihood of post-therapeutic re-
lapse [7]. Other studies have identified that early tumor response to
radiotherapy may be predicted well before completion of dose deliv-
ery [8], supporting the novel development of protocols based on re-
planning and re-targeting of remaining radiation dose midway
during treatment. A similar strategy can be envisioned surrounding
the use of targeted chemotherapies in advanced stage NSCLC, where
FDG-PET monitoring of response at all sites of involvement could dis-
tinguish effective versus futile treatments.
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Transarterial tumour therapy means that the arterial route of an
organ is used for selective tumour therapy. Therapeutics usually used
for transarterial tumour therapy are usually small particles, chemo-
therapeutics and radionuclides. Transarterial tumour therapy is most
often performed in primary and secondary liver tumours, and less
often in other organs, like kidney, lung, prostate, uterus, etc.
For primary or secondary hepatic tumours either transarterial (bland)
embolisation (TAE), transarterial chemoembolisation (TACE), hepatic
arterial infusion (HAI) therapy or transarterial radioembolisation (RE)
are the typical transarterial tumour therapies. A recent method that
is still experimental is chemosaturation [1].
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for intermediate stage (BCLC B) hepatocellular cancers (HCC). TACE
utilises the fact that HCCs are perfused to 80 % by the liver artery
and only to 20 % by the portal venous system. TACE uses the arterial
perfusion of HCCs to introduce ischemia and chemotherapeutics into
the tumour to kill tumour cells and to minimise systemic effects for
the patient. TACE was developed in the early 1980s in Japan and
traditionally was a mixture of lipiodol (ethyl ester of iodized fatty
acids of poppy seed oil) and a chemotherapeutic agent (water-in-oil
emulsion) [2]. This so called conventional or lipiodol TACE (cTACE) is
usually completed by intraarterial application of gelatin sponge and
this technique is established as the standard treatment for HCCs
without portal vein invasion as a result of 2 randomised studies using
doxorubicin [3] or cisplatium [4] as a chemotherapeutic agent. Both
studies demonstrated a significant superiority of cTACE compared to
best supportive care.
In the last 15 years 2 new TACE techniques were developed, TACE
with drug-eluting microspheres (DEB-TACE) and TACE using degrad-
able starch microspheres (DSM-TACE). In DEB-TACE the chemothera-
peutic agent is released slowly from the embolising microparticles
reducing the systemic side effects of TACE [5]. This technique
showed a reduction of post-procedural abdominal pain, but failed to
demonstrate a survival benefit compared to cTACE [6].
TACE is also used to stabilize HCC tumors in patients on the waiting
list for liver transplantation, so called “bridge to transplantation”, and
as an adjunctive to thermal local ablative techniques (e.g. radio
frequency ablation (RFA) or microwave ablation (MWA)). The addition
of a TACE before thermal ablation reduces the perfusion induced
“cooling” of the ablation zone and significantly increases local
tumour control and survival when combined with thermal ablation in
HCCs from 3.5 to 7 cm [7].
In recent years TACE spread to other secondary liver tumour, spe-
cially to liver metastasis from gastroenteropancreatic neuroendocrine
tumors (GEP-NETs) and from colorectal cancers (CRC) [8, 9]. In GEP-
NET either a transarterial bland embolisation (TAE) without chemo-
therapeutic agent or a cTACE with doxorubicin is performed in spe-
cialised centers. For CRC liver metastasis DEB-TACE using irinotecan
as loading drug is the established technique for TACE.
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Despite widespread acceptance of ablation and other local interven-
tional radiology (IR) procedures in adult oncology, the applications of
IR in paediatric oncology have until recently been mostly restricted
to biopsy, central venous access and certain forms of supportive care
[1]. In many centres image-guided biopsy has essentially replaced
surgical biopsy for the diagnosis of extracranial solid tumours in
children.
Attempts to introduce newer therapeutic techniques into paediatric
practice have been hindered by practical, legislative and cultural ob-
stacles [2]. Although a 2014 systematic review found reports of only
28 children treated with ablation techniques for malignant or aggres-
sive benign lesions [3], many more relevant publications have
appeared since then. For the present, at least, the most likely applica-
tion of such techniques is in children with recurrent (or perhaps
unresectable) tumors. Other indications may appear as paediatric on-
cologists become more familiar with the value of these procedures.
One such possibility would be the use of radiofrequency ablation or
cryoablation as an alternative to partial nephrectomy for treatment
of bilateral nephroblastoma (Wilms’ tumour).
Treatment of malignant liver tumours in children with chemoemboli-
zation (TACE) was investigated as long ago as the early 1990s, with
promising results [4]. Three principal indications for TACE in children
have been identified: conversion of unresectable tumours to resect-
ability, as a bridge to transplantation, and as a part of palliation. Des-
pite this, chemoembolization has not so far been incorporated into
any major paediatric liver tumour trial.
Some other IR procedures have an occasional role in the palliative
care of children with cancer [5]. These include techniques for the
management of malignant pleural effusions or ascites, and methods
for delivering analgesic drugs or nerve blocks.
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With the widespread use of prostate-specific antigen screening and
increasing life expectancy, more men are being diagnosed with local-
ized, low-risk, low-grade prostate cancer [1]. As a result, men with
localised prostate cancer and physicians who advise them face a dif-
ficult therapeutic dilemma: surveillance versus radical whole-gland
therapy [2]. The available evidence from randomized controlled trials
demonstrates that there is little to no difference between these
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of 10 years of follow-up [3]. Consequently, deferred treatment such
as active surveillance is an appealing management solution which
maximize the quality of life [4]. Conversely, radical treatment options,
i.e. definitive radiotherapy or radical prostatectomy, come with con-
siderable side effects such as erectile dysfunction and/or incontin-
ence. Focal therapy is a strategy by which the overtreatment burden
of the current prostate cancer pathway could be reduced [2]. This
therapy concept has already been successfully applied to kidney [5],
liver, breast, and lung cancer.
Focal therapy is an emerging local treatment option, which offers
great hopes in term of decreased morbidity associated with standard
whole-gland therapy without jeopardising cancer control [6]. The
challenge of focal therapy is to treat the tumour, sparing the rest of
the prostate, especially near the neurovascular bundles, bladder
neck, rectum and the urethral sphincter, to minimize the potential
morbidity. Concern regarding focal therapy has centered on the
knowledge that prostate cancer is multifocal in origin. In prostate
cancer, a larger dominant lesion is often accompanied by two or
three smaller low-grade lesions. A hypothesis has emerged that the
largest lesion in the prostate — the index lesion — drives disease
progression [7]. The index lesion tends to be associated with the
highest Gleason grade, harbours other pathological determinants of
progression, and has been associated with lymph node metastases
on genetic profiling. If the index lesion could be isolated with reason-
able precision and treatment directed to it alone, then the onco-
logical efficacy of whole-gland treatment might be matched while
minimizing the risk of side effects.
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Over the past five decades, researchers have begun to unravel
many of the molecular pathways that lead to development of
cancer. Through this work we have learned that 90 % of cancers
occur as a result of an acquired somatic mutation while the
remaining 10 % of cancers occur as a result of a hereditary,
germline mutation [1]. Patients with a hereditary cancer predis-
position syndrome often present younger in life than those pa-
tients with a somatic mutation [1].
To date, there are at least 114 known cancer predisposition syn-
dromes [2]. The purpose of this talk is to describe several of the morecommon cancer predisposition syndromes including Li-Fraumeni syn-
drome, DICER 1 syndrome, Beckwith Wiedemann syndrome, tuberous
sclerosis, and Down syndrome [3-7]. For each syndrome, the com-
mon tumours will be described and the current guidelines for screen-
ing will be discussed.
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Pediatric chest and chest wall masses are heterogeneous in etiology
and presentation. Correct diagnosis of chest or chest wall masses is
often challenging. Differentiation between malignant and benign
processes including congenital abnormalities is of essential import-
ance. Overall, primary pediatric pulmonary malignancies are uncom-
mon. However, mediastinal masses and chest wall masses are not
uncommon and should prompt thorough investigation.
In this interactive session we will use a case based approach to dis-
cuss various common and rare pediatric chest neoplasms as well as
non-neoplastic differential diagnoses. In particular we will discuss the
value of correlating the most likely primary site or epicenter of the
lesion with the imaging characteristics as seen on radiography, ultra-
sonography, computed tomography, or magnetic resonance imaging
as well as the age and gender of the child in narrowing down the
differential diagnosis.
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Imaging plays an important role in the diagnosis of an abdominal
mass in a child. Imaging studies need to be performed and inter-
preted in the light of the age of the child, clinical presentation and
history, physical examination and laboratory results.
Ultrasound is a valuable technique for examining the pediatric abdo-
men and should always be the first imaging test to be performed.
Both CT and MRI are modalities with a high burden for the child. The
Cancer Imaging 2016, 16(Suppl 1):28 Page 7 of 34dose of ionizing radiation that comes with an abdominal CT is con-
siderable. For abdominal MR, young children will need to be sedated
or anaesthetized.
Abdominal malignancies in children are rare, with an incidence of 1-
9 per million children per year. The most frequent malignant abdom-
inal tumours of childhood are neuroblastoma, originating from the
adrenal gland or anywhere from the sympathetic nervous system,
nephroblastoma (Wilms’ tumour) from the kidney, hepatoblastoma
from the liver [1-3]. Benign lesions of hemorrhagic, inflammatory or
infectious origin as well as congenital malformations may mimic a
malignancy and a malignant tumour may be mistaken for a benign
lesion [4].
In some cases ultrasound imaging will demonstrate the benign na-
ture of a mass, and exposure of the child to imaging modalities with
a high burden will hence be unnecessary. Whenever ultrasound find-
ings are inconclusive or suggestive of a malignancy, complementary
cross-sectional imaging studies are necessary. CT or MRI should then
be carried out with the highest possible yield of diagnostic informa-
tion and with the ALARA principle in mind [5].
In order to avoid pitfalls, it is important to be aware of the comple-
mentarity of the different imaging modalities and to include all infor-
mation in the conclusion of the report.
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Hepatocellular carcinoma (HCC) is the most frequent primary liver
tumour (80 % - 90 %) and represents more than 5 % of all can-
cers. HCC is the endpoint of a serial transformation beginning
from a dysplastic nodule, often triggered by chronic liver inflam-
mation and cirrhosis. The progression from dysplastic nodule to
HCC implies not only morphological changes but also vascular
transformations, with process of neoangiogenesis leading to an
increased number of unpaired arteries, progressive reduction of
hepatocellular function [1].
Dynamic T1w during the arterial phase is of outmost importance for
the detection of small HCCs [2]. Typically, HCCs demonstrate arterial
enhancement and venous washout showing later hypointensity.
However, HCCs smaller than 2 cm and well-differentiated HCCs fre-
quently have atypical enhancement patterns [3]. In these situations,
the use of liver-specific contrast agents (Gd-BOPTA or Gd-EOB-DTPA)
can be helpful. While dynamic imaging of HCC with liver-specific MR
contrast agents is similar to what observed with conventional CA, de-
layed hepatobiliary phase (HBP) imaging reveals a number of differ-
ent enhancement patterns, with both iso-, hypo- and hyperintense
patterns possible.
The signal intensity of HCCs on the HBP images has been recently
considered as a potential imaging biomarker [4]. HBP hyper-intense
HCCs have been reported to have histologic features related with fa-
vorable outcomes more frequently than HBP hypointense HCCs,
showing higher grades of tumor differentiation, a lower rate of
microvascular invasion [4], lower levels of expression of several kinds
of poorer prognostic immunohistochemical markers [5].The hepatobiliary phase images can increase the value of Gd-
enhanced MRI in the diagnosis of early stage HCC. The use of liver
specific contrast agents increase the sensitivity and accuracy for
small HCCs either with Gd-EOB-DTPA [6] and with Gd-BOPTA [7].
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Ultrasound plays an important role for monitoring development of
liver cirrhosis and for screening of hepatocellular carcinoma (HCC).
Recent developments of US including ultrasound elastography (USE)
and multimodality fusion imaging may play an important role for
management of patients with chronic liver disease and liver cirrhosis
[1, 2]. Prognosis of patients with chronic liver disease is determined
by the extent and progression of liver fibrosis, which may ultimately
lead to hepatocellular carcinoma (HCC) [3]. Although liver biopsy (LB)
is regarded as the gold standard to estimate the extent of liver fibro-
sis, it has several limitations, the foremost being its invasiveness and
sampling bias due to its limited sampling volume. Among the several
non-invasive methods for assessing liver fibrosis recently developed,
MR elastography and USE techniques including transient elastogra-
phy (TE), point or two-dimensional shearwave elastography (SWE)
provide an accurate representation of the extent of liver fibrosis [2,
4]. Recent studies have demonstrated the usefulness of USE for
assessing the risk of HCC development and HCC recurrence after
curative treatment, and developed novel models to calculate the risk
of HCC development based on stiffness values. In addition, with the
technical development of ultrasonography (US), electromagnetic
tracking-based fusion imaging of real-time US and computed tomog-
raphy/magnetic resonance (CT/MR) images has been used for percu-
taneous hepatic intervention such as biopsy and radiofrequency
ablation (RFA) [5]. Real-time multimodality fusion imaging can en-
hance lesion detectability and reduce the false positive detection of
Cancer Imaging 2016, 16(Suppl 1):28 Page 8 of 34focal hepatic lesions with poor sonographic conspicuity, and may
improve efficacy of the percutaneous RFA of liver tumors using an
overlapping ablation technique or multi-electrode technique [1].
Volumetric and fusion imaging should improve the therapeutic man-
agement of malignant liver lesions and particularly percutaneous
guidance of thermo-ablation procedures.
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Positron emission tomography (PET) and magnetic resonance
(MR) imaging until recently has been performed by separate PET
and MR devices with temporal delay between these two acquisi-
tions. However, various recent hardware solutions have been
developed by different vendors which permit simultaneous or
near simultaneous PET and MR acquisition. However, the clinical
translation of this modality for oncologic imaging requires not
only identifying the appropriate clinical indications, but also un-
derstanding various components involved in establishing a PET/
MR service which include physical installation of the system, equipment
safety, clinical workflow, technician and physician training, and monet-
ary reimbursement.
The current and potential clinical indications for imaging of meta-
static disease can be broadly classified as follows:
(1). Simultaneous local and distant staging of cancers such as
rectal cancer and gynecologic malignancies. Here high
spatial resolution of MRI provides information about local
extent of the disease and PET is used predominantly for
distant staging.
(2). Problem solving for potential metastatic disease such as for
small liver lesions, small lymph nodes, or bone marrow
involvement. Additional information provided by MRI and PET
can better characterize lesions and improve confidence in
diagnosing presence or absence of metastatic disease.
(3). Assessment of treatment response. Use of quantitative MR and
PET information can potentially provide synergistic information
in assessing treatment response.
To address these clinical need there are number of operational
considerations such as:
(1). Protocol optimisation.
(2). Workflow in scanning and interpretation of studies.
Some of the technical challenges and limitations that need to be
considered include:(1). Limitation of MRI for lung lesion detection.
(2). Attenuation correction.
(3). Registration of free-breathing PET and breath-hold
thoacoabdominal MR data.
While FDG PET/CT remains the workhorse for diagnosis and manage-
ment of oncologic diseases, early experience shows that PET/MR may
have a complementary role. PET/MR could potentially play a signifi-
cant role in diagnosis and management algorithms of several
malignancies.
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Integrated PET/MR (positron emission tomography/magnetic resonance
imaging) devices have only been recently introduced into routine clin-
ical practice. Compared to PET/CT (computed tomography), the most
widely utilised hybrid imaging technique at present, for which the total
scan duration is only about 20-25 min, the scan duration is rather long
for PET/MR, with 45-60 min for a whole-body examination. Therefore, a
justification for the use of PET/MR, which is more cost intensive while
providing a lower patient throughput, is required.
For malignant lymphoma, a heterogeneous family of cancers for
which PET/MR has already been evaluated, the most obvious
advantage, compared to PET/CT, is the low radiation exposure (about
6-8 mSv, compared to at least 20 mSv for a fully diagnostic, contrast-
enhanced PET/CT examination). This topic is of relevance because
lymphoma is one of the more common malignancies among children
and adolescents, for whom life-long monitoring may be required,
and for whom the risk of development of secondary, radiation-
induced neoplasms must therefore be minimised.
A less frequently recognised advantage of PET/MR is the fact that
DWI (diffusion-weighted imaging) can be incorporated in the exam-
ination. In lymphoma, DWI – even as a stand-alone whole-body tech-
nique – has shown to be only moderately inferior to [18F]-FDG-PET/
CT – both in terms of pre-therapeutic staging and post-therapeutic
restaging/treatment response assessment [1, 2]. Similar to the quanti-
fication of glucose metabolism on [18F]-FDG-PET, DWI offers the abil-
ity to quantify diffusion restriction by means of apparent diffusion
coefficients, and thus, indirectly quantify cell density. Notably, DWI
has also performed particularly well in some of the lymphoma sub-
types for which [18F]-FDG-PET is currently not recommended by the
ICML (International Conference on Malignant Lymphoma), which in-
cludes marginal zone lymphomas, SLL/CLL (small lymphocytic lymph-
oma/chronic lymphocytic leukemia), Morbus Waldenström, and
mycosis fungoides [3]. It is thus not surprising that the current litera-
ture suggests not just a non-inferiority of [18F]-FDG-PET/MR, com-
pared to [18F]-FDG-PET/CT, but a moderate superiority, at least when
the entire spectrum of lymphomas is taken into account [4].
Another advantage of PET/MR lies in the fact that dynamic or mul-
tiple time-point PET can be easily integrated into the work-flow. De-
layed time-point [18F]-FDG-PET, for instance, has been shown to
improve the detection of slowly-growing, indolent lymphomas with
no, or low, FDG uptake, such as MALT lymphoma [5], the third most-
common type of Non-Hodgkin lymphoma.
With regard to MALT lymphoma, SLL/CLL, and possibly, several other
lymphoma subtypes for which [18F]-FDG is of limited value, novel
PET tracers might be used in the context of PET/MR. This includes
[68Ga]-Pentixafor, a radiotracer that specifically attaches to CXCR4
chemokine receptors [6]. CXCR4 receptors are overexpressed on the
Cancer Imaging 2016, 16(Suppl 1):28 Page 9 of 34cell surfaces of different tumours, including those derived from the
lympho-proliferative system, and regulate, among other things, cell
migration. In an ongoing study presently performed at our institu-
tion, [68Ga]-Pentixafor has, so far, shown a very high sensitivity for
detection of MALT lymphomas.
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Currently national and international guidelines for imaging proce-
dures for high-risk and advanced prostate cancer (PCa) include
abdomino-pelvic cross sectional imaging, multiparametric prostate
MRI, bone scintigraphy and in the case of therapy monitoring of
mCRPC whole body cross-sectional imaging mainly by means of
computed tomography. Positron emission tomography (PET) has be-
came increasingly important in the work-up of prostate cancer. In
the past, the use was mainly limited to radiolabbeled Choline-
derivates which showed considerable limitations and did not always
meet the diagnostic needs.
Recently, a 68Gallium-labelled ligand of the prostate-specific mem-
brane antigen (68Ga-PSMA) has been introduced in PET-imaging
of PCa with first promising results. Due to relatively exclusive ex-
pression of PSMA in prostatic tissue as well as increased expres-
sion in PCa 68Ga-PSMA was reported to exhibit a favourable
lesion to background ratio compared to presently used choline-
or fluorodesoxyglucose-based PET examinations. Together with
the novel development of combined PET/MR, the combination of
excellent morphological detail, multiparametric functional infor-
mation and molecular PET data might lead to a significant im-
provement in detection and staging of PCa and thus may help to
optimise oncological treatment. The talk encompasses:
Teaching and learning contents of the talk will include:1. The molecular basis of prostate cancer imaging targeting the
prostate-specific-membran antigen (PSMA), review of the
various PSMA-tracers [1] [2].
2. The diagnostic performance and potential role of PSMA PET/CT
and PET/MR for high-risk primary and advanced prostate
cancer [3] [4].
3. Comparison of the use of PSMA PET-imaging with conventional
imaging as included in guidelines [3,5].
4. Discussion of non-routine applications (e.g. biopsy targeting,
radioguided surgery, radioreceptor therapy using Lu177-PSMA)
[6] [7].
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Traditional chemotherapy is directly introducing tumour cell death
and later a shrinkage of tumour masses throughout the body. So re-
sponse evaluation criteria, like WHO, RECIST or Lugano criteria, used
for evaluation of response to chemotherapy rely on tumour shrink-
age as a sign of efficacy [1-4]. Additionally in these criteria the ap-
pearance of new lesions or progressing non-target lesions is
indicating progress of disease independent of the changes in the tar-
get lesions.
Ipilimumab, a monoclonal antibody that blocks cytotoxic T-
lymphocyte-associated antigen 4 (CTLA 4), was the first immuno-
therapeutic agent that showed in clinical phase II trials survival
benefits and successful tumour therapy in patients with advanced
malignant melanoma [5]. In the study treating malignant melan-
oma it was shown that superficial and organ metastasis in some
patients even increase in size or new lesions appear, whereas
these patients later show very good response and survival benefit
in the following course of the study. Following traditional re-
sponse criteria these patients would have been assessed as pro-
gressive disease (PD) and excluded from the study (or dropped
out from the progression free survival (PFS) group). This increase
Cancer Imaging 2016, 16(Suppl 1):28 Page 10 of 34of size and appearance of the lesions is thought to be a result of
lymphocyte and macrophage invasion into the tumour and is
called “pseudoprogression”.
Using the results from the mentioned study new criteria,
immune-related response criteria (irRC), were defined by Wolchok
et al. [5]. These criteria base on bi-dimensional target lesion
measurements analogue to WHO criteria. In contrast to other cri-
teria new tumour lesions not directly trigger progressive disease
(PD). The bi-dimentional measurements of new appearing lesions
will be included into the sum of product tumour diameters (SPD)
of the defined target lesions at baseline. Additionally every pro-
gressive disease (PD) must be confirmed by a repeated imaging
with minimum 4 weeks interval. Both new rules should reduce
the pseudoprogression in the tumour response assessment in
immunotherapy.
In the last years these new rules have been integrated into the
mono-dimensional RECIST criteria to evaluate immunotherapy. For
these new mono-dimensional criteria no commonly accepted term
exists. This modification is called immune-related RECIST (irRECIST),
immune-modified RECIST, modified RECIST (mRECIST) or irRC 2014.
Personally I prefer the term immune-related RECIST (irRECIST),
because it best reflects the immunotherapeutic modification of the
established RECIST system.
In the last years many new immunotherapeutic agents have been
investigated in clinical studies, like pembrolizumab, nivolumab
(anti-programmed cell death protein 1 (anti-PD1) antibodies),
atezolizumab (anti-PD-L1 (programmed cell death-ligand 1)), ipili-
mumab (anti-CTLA 4), alemtuzumab (anti CD52), ofatumumab and
rituximab (anti-CD20).
Current studies are investigating these checkpoint inhibitors of the
immune system in colorectal cancer, malignant melanoma, breast
cancer, non-small-cell lung carcinoma, bladder cancer, renal cell
carcinoma, lymphoma and leukaemia.
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The measurement of response following cancer treatment is critical
in order to ensure the most appropriate and optimal management
for each patient. This applies to daily practice as well as to patients
taking part in clinical trials. The main difference between these two
settings is that the recording of response in the trial setting needs to
be done in a highly uniform and rigorous manner that is standar-
dised and reproducible.
The detection of response, whether for clinical trial reporting or for
daily practice, requires a few important pieces of information:1. We need to know the date of baseline scan immediately prior
to a new treatment being started.
2. We need to know what disease was present at the time of the
baseline scan. In the case of clinical trial reporting, we need to
know which target lesions were selected at baseline.
3. We need to know if there were any important events that
could alter the scan appearances (for example drainage of
ascitic fluid or interval surgical resection during the course of
treatment).
4. We need to be aware of the findings on each scan from
baseline to the time of the scan that is currently being
reported, in order to be certain that the nadir (the smallest
recorded diameter of target lesions) is correctly identified.
For the purposes of clinical trial reporting, it is essential to know
which reporting criteria are being used for the trial. Most trials use
RECIST 1.1; this updated version addresses some of the issues with
the first RECIST, such as defining the measurement of lymph nodes.
However, some trials do still use the original RECIST, usually in dis-
eases that have a predominance of metastases in one organ, such as
the liver in gastrointestinal neuroendocrine tumours. In this case, be-
ing restricted to only two lesions in one organ becomes restrictive
and potentially not representative of changes that may be occurring.
The initial selection of target lesions at baseline lays the foundation
for the future reports. Clear guidance on the selection of lesions
should be adhered to. The target selection rules will be reviewed in
the course of the workshop. Clear recording of the selected target le-
sions and the recording of the sum of target lesions will help in fu-
ture reports.
A very helpful aspect of the RECIST 1.1 paper is the section on “Fre-
quently asked questions”. Several of these more challenging aspects
of trial reporting will be reviewed, together with examples.
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Response Evaluation Criteria for Solid Tumours (RECIST) guidelines
were introduced in 2000 and updated in 2009 to provide a standar-
dised method for assessing response to treatments [1,2]. Tumour
burden is measured using sum of the diameters with uni-
dimensional measurements. The response categories are those of
complete response, partial response, stable disease and progressive
disease. Though the RECIST criteria are intended for use in the clin-
ical trial setting, onocologist increasingly rely on RECIST based mea-
surements to make clinical management and therapeutic decisions
in daily clinical practice.
RECIST guidelines are therefore widely employed, however, they
have well recognised limitations and pitfalls. Tumours that are irregu-
lar, or show diffuse infiltration or poorly visualised eg with fatty liver,
can all be difficult to measure in a reliable and reproducible way.
Tumour with non-spherical growth pattern can be difficult to serially
follow up and assess response. The categories for the response cri-
teria are arbitrarily defined and may not correlate with clinical out-
come. Morphological characteristics and tumour heterogeneity are
not taken into consideration. Functional or physiological change with
response is not assessed / measured in RECIST. Reliance of response
is based exclusively on tumour size and clinical beneficial chemother-
apeutic effects may occur without reduction in tumour size eg many
new targeted therapies have anti-angiogenic effects and result in
symptomatic improvement in patients. Similar immue mediated re-
sponse may artificially result in short term increase in tumour size or
small new lesions. Treatment effects such as necrosis, cystic change
and haemorrhage can result in artificial change in tumour size. Mixed
and differential response is simplified in the response assessment in
RECIST. Bone disease without significant soft tissue and cystic tumour
it can be difficult to assess change with the tumour.
Cancer Imaging 2016, 16(Suppl 1):28 Page 11 of 34The limitations in RECIST guidelines have led to the publications and
developments in modified RECIST and other response criteria to
overcome these shortfalls.
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Introduction: The Deauville Score (DS) (also referred to as the Deau-
ville criteria) is a standardised five-point scale developed to assess
treatment response in lymphoma. The scale originated from a scor-
ing system developed at St Thomas’ Hospital and was at that time
named the SELCN (South East London Cancer Network) Score. Fol-
lowing initial work confirming high concordance of the reporting cri-
teria between reporters, particularly with respect to use in clinical
trials [1], the scoring system was adopted as the preferred method
for reporting of response assessment in lymphoma at the First Inter-
national Workshop on PET in Lymphoma in Deauville, France, in
2009 [2]. Its use has subsequently been validated in Hodgkin, diffuse
large B-cell and follicular lymphomas [3,4,7].
Since then the DS has been increasingly used in clinical practice and
in national and international trials as a simple, quick and reprodu-
cible method to assess response to treatment in lymphoma, with
good interobserver agreement reported in several studies [5, 6, 7]. It
has also been shown to have predictive and prognostic significance.
How to use the Deauville Score: To use the DS, the reader makes an
initial visual assessment to identify the residual area(s) of focal up-
take at original sites of disease, in comparison to a pretreatment
baseline scan and measures the maximum standardised uptake value
(SUVmax) of these areas. The reader then draws two background re-
gions of interest. The first is drawn within the aortic arch (taking care
to exclude vessel walls and associated calcification) and represents
mediastinal blood pool. A second region is drawn in a large region
of normal liver to determine the normal liver SUVmax.
The five-point scale scores the most intense uptake in a site of initial
disease as:
1. no uptake.
2. uptake ≤mediastinal blood pool.
3. uptake >mediastinal blood pool but ≤ liver.
4. uptake moderately higher than liver*.
5. uptake markedly higher than liver and/or new lesions**.
X new areas of uptake unlikely to be related to lymphoma.
*moderately is uptake up to 3 times greater than the SUVmax in a
large region of normal liver.
**markedly is uptake greater than 3 times the SUVmax in a large
region of normal liver.
When to use the Deauville Score: Recently published guidance rec-
ommends that the DS is used for reporting response assessment
both at interim and end of treatment [8]. Whilst the majority of
lymphomas are FDG-avid, published experience is predominantly
with Hodgkin, diffuse large B-cell and follicular lymphomas. Further-
more, in specific circumstances, there is now evidence that interimPET assessed using the DS can be used to guide response adapted
therapy [9, 10].
Reporting template: The presentation will also introduce the idea of
a reporting template for response assessment in lymphoma incorpor-
ating the ideas discussed in the talk.
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There is no doubt that imaging is a central tool in contemporary can-
cer care. From staging to assessing treatment response and follow-
up, it would be difficult to imagine a patient with cancer in 2016
who has not undergone some form of imaging as part of their dis-
ease evaluation. This paradigm has solidified the place of oncologic
imaging as a sub-specialty, but it has also lead to challenges related
to augmenting the knowledge of those practicing it in areas that are
not classically considered mainstream radiology. These continuously
evolving topics are definitely relevant to oncologic imaging, such as
molecular biology, genomics, proteomic and immunotherapy, just to
name a few. All these have direct or indirect implications on the im-
aging findings or their interpretation, and as such should be part of
the opportunities for lifelong learning. In this session, we will discuss
resources for increasing radiologists’ knowledge of these topics.
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Life long learning in medicine is a process of continuously scrutinis-
ing our practice, recognising gaps in our understanding and actively
acquiring new knowledge to ensure that we are practicing medicine
to the highest professional standards. Life long learning is self-
directed, personal, active, participatory and reflective. However, the
busy working life and competing demands for our time may make it
difficult to realise these aims. The key barriers to success include diffi-
culty with personal reflection, environment strain, competing de-
mands, difficulty with goal generation, and problems with plan
generation and implementation. In addition, lack of access to high-
quality learning materials may also impede progress.
E-learning is increasingly recognised as an effective way to deliver
learning material for continuous medical education. As Oncologic Im-
aging is an emerging sub-speciality discipline, there are few sites dedi-
cated to cancer imaging. The ICIS e-portal aims to address this gap by
providing high-quality carefully curated learning material to the Society
Membership. This will include dedicated online cancer imaging course,
cases crowd-sourced from the ICIS Online Learning Community and de-
velopment of the ICIS Ring of Excellence case archives.
O25
Benign lesions that mimic pancreatic cancer
Jay P Heiken (heikenj@mir.wustl.edu)
Mallinckrodt Institute of Radiology, Washington University School of
Medicine, St. Louis, MO 63110, USA
Cancer Imaging 2016, 16(Suppl 1):O25
Chronic inflammatory processes involving the pancreas, normal ana-
tomic variants and some benign neoplasms can mimic pancreatic
malignancy. Some of these processes are discussed below.
Intrapancreatic splenule appears as a round enhancing mass within
the tail of the pancreas. Because of its vascularity it can be mistaken
for a pancreatic neuroendocrine tumor. One of the keys to diagnosis
is recognition that the mass has enhancement, attenuation and/or
signal intensity characteristics that parallel the spleen on all image
acquisitions. The diagnosis can be confirmed with a technetium
99 m heat-damaged red blood cell scan, which demonstrates radio-
tracer uptake within the mass.
Mass-forming chronic pancreatitis, particularly autoimmune pancrea-
titis, frequently is misdiagnosed as pancreatic adenocarcinoma or a
neuroendocrine tumour. Most commonly mass-forming chronic pan-
creatitis is isoattenuating/isointense during both the pancreatic and
hepatic parenchymal phases of contrast enhancement. In contradis-
tinction, pancreatic adenocarcinoma typically is hypoattenuating/
hypointense during both enhancement phases; however, approxi-
mately 10 % of pancreatic adenocarcinomas are isoattenuating/isoin-
tense during both phases. On MR cholangiopancreatography (MRCP)
the pancreatic duct within the mass-forming pancreatitis may be vis-
ible but narrowed (duct-penetrating sign), whereas the duct within
pancreatic carcinoma often is occluded. One study has shown the
duct-penetrating sign to be 94 % accurate in distinguishing the two
entities. Elevation of serum IgG4 is the best serological marker for
autoimmune pancreatitis (sensitivity 73-75 %; specificity 93-95 %);
however, approximately 10 % of patients with pancreatic cancer may
have elevated IgG4.
Pancreatic serous cystadenoma is a benign mass that consists of nu-
merous tiny cysts separated by glandular tissue and fibrous stroma.
On CT it appears as a well-circumscribed hypoattenuating mass with
varying degrees of contrast enhancement, depending on the size of
the cysts and the proportion of cystic to glandular tissue. In most
cases it is not difficult to distinguish this multicystic lesion from a
solid pancreatic neoplasm; however a small proportion of serous
cystadenomas consist largely of glandular tissue and fibrous septawith only a small proportion of tiny cysts. Such lesions appear hyper-
vascular and may mimic a pancreatic neuroendocrine tumor. Clues
to the diagnosis include precontrast attenuation value within the
range of fluid and the presence of small cystic areas with the enhan-
cing mass. Heavily T2 weighted images may help demonstrate the
microcystic nature of the mass in some cases. In addition, this diag-
nosis should be considered if the mass is found incidentally in an
elderly individual or a patient with von Hippel Lindau disease.
Focal fatty replacement of the pancreas occasionally can mimic a pan-
creatic tumor, appearing as a focal hypoattenuating area on CT. The
most common location is the anterior portion of the pancreatic head.
Clues to the correct diagnosis include triangular shape and absence
of mass effect or ductal obstruction. The presence of fat can be con-
firmed by demonstrating reduction in signal intensity on the op-
posed phase of chemical shift MR imaging.
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Accurate staging of many malignancies including pancreatic adeno-
carcinoma is essential for determining patient treatment. Only a mi-
nority (15-20 %) of patients with pancreatic carcinoma is resectable
at the time of presentation and patients with a curative resection
with margin negative resections have a better prognosis than those
with residual macroscopic disease after resection. So it is crucial to
separate these tumors into those who are resectable, borderline re-
sectable and unresectable and metastatic groups. The commonly
used staging systems in the United States are those put forward by
the American Joint Committee on Cancer [AJCC] and the National
Comprehensive Cancer Network [NCCN]. The AJCC system is based
on the TNM system, with the T based on location and size and local
extent, N, nodal and M, distant metastasis. Vascular contact/abut-
ment is described as + or < or > 1800. However there are a few pertin-
ent findings that are not included in these staging systems which are
essential for surgical planning and determining resectability status.
These include the presence of venous thrombus, tumour contact with
common hepatic artery to the origins of the right and left hepatic arter-
ies, tumour contact with first SMA branch and most proximal draining
vein into the SMV, as well the presence of arterial variants.
Despite the preference of standardized structured or template
reporting over conventional reporting by referring clinicians, its
adoption into daily clinical practice has been slow in coming. The
most commonly used type of conventional or free style reporting,
tends to either “bury” the pertinent information needed for patient
management in lengthy reports which include irrelevant incidental
findings or fail to mention aspects of the findings that are crucial the
treatment and management of the current condition for which the
Cancer Imaging 2016, 16(Suppl 1):28 Page 13 of 34patient was imaged. Structured or template reports on the other
hand can provide relevant information that is essential for patient
management and this is especially true for patients with pancreatic
carcinoma, given the variability in expertise and definition of disease
extent amongst different readers.
In an effort to move the concept of structured reporting, a consensus
statement was issued in 2014 by both the Society of Abdominal
Radiology and the American Pancreatic Association, regarding a
reporting template for pancreatic adenocarcinoma. This has been
jointly published simultaneously in two major journals: the American
Journal of Gastroenterology and Radiology.
Some initial studies have shown the value of standardized structured
reporting in tumour staging and surgical planning, both to our
referring clinicians as well as radiologists and radiology trainees.
Brook and colleagues compared the results of structured versus non-
structured reporting of findings of MDCT (multidetector computed
tomography) for the staging and subjective assessment of resectabil-
ity for pancreatic cancer and showed that surgeons were confident
regarding decisions regarding tumor resectability when structured re-
ports were available than with nonstructured reports. We and others
have now started to work on developing a similar working reporting
template with the Society of Abdominal Radiology through disease-
focussed panels (DFP’S) s for cystic pancreatic lesions.
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Intraductal papillary mucinous neoplasms (IPMNs) are a group of
exocrine mucin-producing tumours, diagnosed at a mean age of
60 years, with a male prevalence [1].
IPMN arises from the epithelium of the pancreatic ductal system and
can display the full spectrum of histologic dysplasia, including hyper-
plasia, adenoma, borderline tumour, in situ or invasive carcinoma [2].
Three types of IPMNs have been described [1]: the main duct type; the
branch-duct type and the mixed type, which meet the criteria for both
MD-IPMN and BD-IPMN. There are significant differences in frequencies
of malignancy in IPMNs according to the morphological types, higher
for MD-type (mean 61.6 %) and lower for BD-type (25.5 %) [3].
A clear differentiation between IPMN lesions with different patho-
logic expression can be difficult, unless clear evidence of malignancy
is present. However, some imaging findings can be suggestive of ag-
gressive behavior of the IPMN [3].
High risk stigmata suggest the high possibility that the lesion is ma-
lignant, thus requiring surgical resection if Patient is fit: main duct
diameter > 10 mm for MD-IPMN, the presence of solid enhancing
nodules within the cyst in BD-IPMN, or obstructive jaundice in pres-
ence of a cystic lesion of the pancreatic head. Worrisome features
suggest the possibility that the lesion could evolve in malignant, thus
requiring further workup by EUS, to better risk-stratify the lesion, anda strict follow-up: cyst > 3 cm, thickened enhanced cyst walls, MPD
size of 5-9 mm, non-enhancing mural nodules, abrupt change in the
MPD caliber with distal pancreatic atrophy, and lymphadenopathy.
The management of IPMN is mainly based on the location (MD- and
mixed type-IPMN versus BD-IPMN), the size of the largest cyst in BD-
IPMN, the presence of “high risk stigmata” (main duct diameter >
10 mm for MD-IPMN, the presence of solid enhancing nodules within
the cyst in BD-IPMN, or obstructive jaundice in presence of a cystic
lesion of the pancreatic head) or “worrisome features” (cyst of >
3 cm, thickened enhanced cyst walls, MPD size of 5-9 mm, non-
enhancing mural nodules, abrupt change in the MPD caliber with
distal pancreatic atrophy, and lymphadenopathy). Moreover, risk
stratification for age and fit for surgery must be considered.
Patients with BD-IPMN and cysts of >3 cm and no “worrisome fea-
tures” can also be considered for EUS to verify the absence of thick-
ened walls or mural nodules, particularly if the patient is elderly,
while if patient is young and fit for surgery, surgery should be
strongly considered. Patients with BD-IPMN and cysts of <3 cm and
no “worrisome features” should be considered for observation ac-
cording to size stratification [3].
MD-IPMN with MPD dilation of 5-9 mm can also be considered as a
worrisome feature, with a recommendation of evaluation, but no im-
mediate resection [3].
Imaging plays a pivotal role in the management of patients with
IPMNs, with the different imaging techinques offering specific im-
aging features. However, MRI with MRCP is the leading imaging tech-
nique, either in the initial assessment and in the follow-up [4-7].
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Pancreatic neoplasms are a wide group of solid and cystic lesions
with different and sometimes characteristic imaging features, clinical
presentations and management.
Cystic pancreatic neoplasms comprise serous neoplasms, which are
almost always benign, mucinous cystic neoplasms and intraductal
papillary mucinous neoplasms, which can vary from benign to frankly
malignant lesions, and solid pseudopapillary tumours.
Cancer Imaging 2016, 16(Suppl 1):28 Page 14 of 34Serous cystadenoma (SCA) is a cystic tumour with a typical multilocu-
lar “honeycomb” architecture due to the presence of multiple micro-
cysts (<20 mm), thin walls and multiple septa oriented toward a
central scar. The typical lobulated, “cloud-like” morphology is usually
clearly depictable at imaging. The cystic content is anechoic at US,
hypodense at CT and hypointense on T1-weighted images at MR; T2-
weighted images clearly demonstrates the microcystic pattern.
After intravenous administration of contrast material, the hypervascu-
larization of the central scar and of internal thin septa may be seen.
SCA does not communicate with the pancreatic ductal system and
this can be well demonstrated at MRCP: this finding remains crucial
for the differential diagnosis in respect to branch duct IPMNs.
SCA uncommon presentations are: macrocystic and unilocular; pseu-
dosolid; huge dimensions.
Mucinous cystic neoplasms (MCNs) are pancreatic cystic tumors with
different degress of malignancy. They show clear female sex predilec-
tion and usually appear as a single lesion with a rounded “ball-like”
morphology, usually located in the body-tail of the pancreas prob-
ably due to its close position in respect to the rudimental ovary, and
without communication with the pancreatic ductal system. Mucinous
cystadenoma (MCA) usually presents as a macrocystic lesion, with ir-
regular septa, thick walls and complex content that can be corpusco-
lated, viscous and dense mainly owing to mucinous content. This
content makes very often the lesion heterogeneously hypoechoic at
US, hypodense at CT and slightly hyperintense on T2-weighted im-
ages. On T1-weighted images, the signal intensity can vary from
hypointensity, more common, to hyperintensity depending on mucin
concentration. MRCP clearly demonstrates the lack of communication
with the pancreatic ductal system. Differing from SCA, on post-
contrast imaged, the intralesional septa are disorganised and periph-
erally located, describing a “bridge” along the cystic wall with a
“pseudonodular” appearance. Peripheral calcifications along the thick
wall can be detected, especially at CT .
MCA uncommon presentations are: uncommon site and gender;
disepithelized.
The purpose of this paper is to present common and uncommon
clinical and radiological presentations of cystic pancreatic tumors
providing examples of multi-modality imaging approach with patho-
logic correlations, thus describing the histopathological bases on
which it can be explain the peculiar imaging features, in order to
avoid relevant misdiagnosis and to improve lesion diagnosis and
management.
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Diffusion-weighted MR imaging (DW-MRI) is a challenging noninvasive
MR technique that shows the Brownian motion in the extracellular
extravascular space providing functional and microstructural informa-
tion of the underlying tissue. In neuroradiology this technique is
already an established method for the detection of an acute stroke,
however, extracranial applications gained importance only in recent
years. In head and neck radiology DW-MRI has several potential appli-
cations as an additional and comprehensive tool next to conventional
MRI providing information on morphological alterations of the under-
lying tissue. It can be applied for the functional evaluation of the saliv-
ary glands, for the detection and characterisation of tumours, for lymph
node staging, as well as for the differentiation between recurrent can-
cer and posttherapeutic changes after radiation therapy [1]. Further-
more, its potential for follow-up of patients undergoing radiation
therapy of head and neck tumours might help to predict outcome at
an early time point before morphological changes that occur usually
relatively late in the time course of treatment.
Lower apparent diffusion coefficient (ADC) values are reported in
most malignant compared to benign lesions in the head and neck
region in adults and children [2].For nodal staging DW-MRI has shown promise to be able to detect
lymph node metastases even in subcentimetric nodes with lower
ADC values compared to normal or reactive nodes. Early response to
treatment follow up is reflected in an ADC increase in the primary
tumour and nodal metastases; whereas non-responders tend to reveal
only a slight increase or even a decrease in ADC during follow up [2].
However, optimization and standardisation of DWI technical parame-
ters, comparison of DW images to morphological images and increas-
ing experience are prerequisites for successful application of this
challenging technique in the evaluation of various head and neck
pathologies (2).
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Complications of radiotherapy are important cause of morbidity and
mortality in head and neck cancer survivors and may be exacerbated
by the addition of chemotherapy. These complications may be symp-
tomatic or found incidentally during imaging surveillance. It is im-
portant to be aware of these radiation induced complications as they
may require treatment and also they should not be mistaken for re-
current tumour. The head and neck is a complex region and treat-
ment induced complications involve many different structures.
Examples of complications related to radiotherapy will be illustrated
to show the broad range of abnormalities which can be found at the
following sites-
1) Neurological tissues including the cranial nerves and temporal
lobes (white matter injury, necrosis, cysts and brain abscess).
2) Osteoradionecrosis and osteomyelitis of the skull base,
mandible and cervical spine.
3) Mucositis involving the pharynx and paranasal sinuses
(including polyps and mucocoeles).
4) Vascular damage to the arteries (stenosis, pseudo aneurysm
and carotid blow-out).
5) Glandular tissues (salivary and pituitary)
6) Radiation induced neoplasms (sarcoma and squamous cell
carcinoma).
The lecture will be interactive and will discuss a wide range of radio-
therapy related complications, including some that mimic tumour
recurrence.
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Modern neuroimaging techniques represent an essential tool in the
evaluation of paediatric brain tumours, the second most common
malignancy of childhood after leukaemia [1].
Conventional MRI is the imaging modality of choice for brain tumour
identification and characterization but has limitations in distinguish-
ing neoplastic from non-neoplastic lesions, defining tumour grade,
guiding biopsy sampling, assessing treatment response, and predict-
ing patient outcome [2]. Advanced MRI modalities, such as diffusion
weighted imaging (DWI), perfusion weighted imaging (PWI) and
magnetic resonance spectroscopy (MRS) have improved our under-
standing of brain tumours, overcoming some of the main limitations
of conventional MRI. DWI gives information about the apparent diffu-
sion coefficient of water and provides an opportunity to examine
differences in cell density and tissue structure. PWI measures
hemodynamic properties, such as tissue blood volume, and provides
an indirect estimation of the degree of tumour angiogenesis. MRS es-
timates the levels of various metabolites within brain tissue that may
be helpful for evaluating tumour aggressiveness [3]. Beyond MRI,
metabolic imaging with PET provides further insights into tumour
biological activity, especially when correlated with MRI; indeed, PET
imaging combined with MRI, either by off-line co-registration or via
hybrid PET/MR systems, is emerging as a valuable imaging modality
not competing with but rather complementing MRI [4]; depending
on the radiotracer used, different molecular processes can be
assessed and a growing body of evidence supports the promising
role of radiopharmaceuticals that target amino-acid transport, such
as 11C-methionine (MET), 18F-dihydroxyphenylalanine (DOPA) and
18F-fluoroethyltyrosine (FET) [5,6]. Increased radiolabeled amino acid
uptake in brain tumours correlates with increased use of amino acids
for energy, protein synthesis, and cell division [4] and has proven ad-
vantageous over traditional 18F-fluorodeoxyglucose (FDG) because
of the higher tumour to normal tissue uptake ratio [7]. Furthermore,as brain tumour uptake of amino acid tracers is predominantly deter-
mined by selective transport carried out by amino acid transporters,
brain tumour depiction does not depend on the status of the blood-
brain barrier, thus allowing amino acid uptake to occur in both en-
hancing and non-enhancing tumour components [8]. In the last few
years fluorinated tracers such as 18F-DOPA and 18F-FET have
emerged as alternative radiolabeled compounds to 11C-MET, given
their longer half-life which allows a more widespread application
even to centres without an on-site cyclotron.
Both tracers have been demonstrated to improve paediatric brain
tumour management including tumour diagnosis, treatment plan-
ning, assessing response to treatment and post-treatment surveil-
lance [6,9,10].
Integration of information obtained by MRI and PET should be per-
formed by neuroradiologists and nuclear medicine physicians work-
ing in close collaboration, so as to properly appreciate and integrate
the whole amount of diagnostic information and to offer clinicians
more readily available information for treatment decision-making.
The most relevant applications of PET/MR imaging in paediatric brain
tumours is the focus of the present work, with emphasis on diagnosis
and surveillance of paediatric gliomas.
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There are many key elements necessary to maximise the clinical util-
ity of diagnostic imaging exams, including a pertinent clinical indica-
tion, adequate technical acquisition, accurate interpretation and
effective communication of the imaging findings. The literature sug-
gests that structured reporting in radiology leads to clearer and more
thorough communication of relevant diagnostic findings than does
conventional, free-form reporting. In a study of body oncologic CT
examinations, structured reports were given significantly higher
Cancer Imaging 2016, 16(Suppl 1):28 Page 16 of 34satisfaction ratings by both radiologists and referring physicians com-
pared to “free-form” reports [1]. Barbosa et al. found that in addition
to being preferred by the majority of the radiologists and endocrinol-
ogists participating in a study evaluating thyroid ultrasounds, the use
of structured reporting resulted in improved standardisation of thy-
roid finding descriptors [2]. A study of coronary CT angiograms found
an improved inter-observer agreement for the number of vessels
with significant stenosis when a structured reporting software which
required the radiologist to explicitly state which vessels were in-
volved was used [3]. Other structured reporting software with fea-
tures such as drop-down menus which facilitate data entry and
minimize the amount of free-text entries have been shown to aid
not only data comprehension but also reduce the length of time re-
quired for aortic aneurysm imaging [4].
However, the benefits of structured reporting cannot be accepted
dogmatically. An accurate interpretation reported in “free-form” style
is more clinically useful than a structured report containing errone-
ous information. Furthermore, the terminology used in structured re-
ports also requires standardisation. Khorasani et al reported poor
agreement between radiologists and non-radiologists in the inter-
pretation of the most commonly used phrases in radiology reports
[5]. In recent surveys gathering opinions about radiology reports,
20 % of the responding clinicians indicated that they found the lan-
guage and style of radiology reports unclear [6]. Another study found
that referring clinicians may reach different conclusions when read-
ing the same reports [7].
Another important issue relevant to standardised reporting is the ex-
pression of diagnostic certainty. Radiologists are often tasked with
summarising multiple findings and rendering an opinion with
regards to potential explanations for the radiographic findings. There
are scenarios in which no differential diagnoses are warranted and
the findings are reported in terms of the absolute presence or ab-
sence of a pathologic process (e.g. “no fracture”). In other cases the
findings are not definitive, and radiologists need to indicate their
level of certainty for their interpretation of the imaging findings. In a
study of patients with prostate cancer, 38 different terms were used
in MRI reports to express the levels of certainty for the presence of
extracapsular extension, prior to the introduction of a 5-point “cer-
tainty lexicon” [8]. The lexicon not only simplified the communication
of the radiologists’ level of suspicion but also allowed more objective
quantification of the diagnostic performance of MRI for diagnosing
ECE, with a reported area under the curve of 0.85 [8]. The develop-
ment of standardised “lexicons” to indicate the radiologists’ level of
certainty for interpreting the imaging findings should therefore be
considered an integral component of structured reports.
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A structured report is determined by a pre-defined report organisation
based on templates that are used repetitively. Templates containing
preferred common language describe findings and diagnoses. Struc-
tured reporting adds value because it limits inconsistency, avoids con-
fusion and ambiguity. Preferred terms and definitions are used
consistently which aids teaching, research, and clinical practice. Struc-
tured reports can contain tools for radiologists for appropriate content
for any given indication or diagnosis.
Because radiologists may be reluctant to adopt structured reporting,
at our institution we implemented certain tools which were helpful
in assuring the success of such reporting. Group buy in and Involve-
ment in the creation of report templates was used and each subspe-
cialty division developed standardised normal reports. There were also
group financial incentives for adherence to structured reporting. The
MGH standard report includes patient information, date and time,
requesting physician and history, and exam protocol. Templates are
provided for the dictation of the standard normal report for any im-
aging study. Predetermined auto text can be added appropriately.
Our department has also developed clinical decision support tem-
plates for radiologists which integrate standards and best practices
at the radiology point of care. The clinical decision support template
helps radiologists make appropriate recommendations for further im-
aging work up based on best practices and guidelines. Examples in-
clude lung cancer screening, management of thyroid and adrenal
nodules. Algorithms which included decision trees and end points
for recommendations are included. A demonstration of the software
for the clinical decision support tool for lung cancer screening will be
demonstrated during the lecture.
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It is a two way process with the oncologist needing to know information
about the tumour but with the imaging specialist needing good informa-
tion to allow the provision of an accurate and clinically useful report. It is
now a given that cancer management takes part within the multidiscip-
linary process with tumour boards that meet regularly to discuss all new
or difficult refractory cases. The use of agreed clinical protocols will help
to streamline care by ensuring that patients get access to the most ap-
propriate imaging technique and that it is carried out according to stan-
dardised and agreed clinical protocols. The imaging specialist is best
placed to advise which modality is most appropriate and sometimes sev-
eral modalities are required to get the information needed. The oncolo-
gist needs to know the diagnosis, staging and anatomy of the
surrounding organs at risk; and if radiotherapy is being given how to tar-
get the tumour with modern state-of-the-art intensity in the modulated
radiotherapy planning technologies. This is also essential to assess the re-
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treatment is not working so that treatment can be suspended or chan-
ged. For follow-up, imaging is part of the process of looking for evidence
of recurrence. After radiation treatment it may be challenging to deter-
mine whether there is recurrence or post-radiation fibrosis and the im-
aging specialist plays a vital role in helping to determine this. Clinical
trials play an important part of the oncologist workload and so there are
particular issues in assessing response to treatment which have to com-
ply with international guidelines and ruling from the regulatory bodies.
Imaging specialists require time to get used to the RECIST criteria. Many
of the new cancer drugs have brought with them their own fresh chal-
lenges as classical responses not necessarily seen. Tumours may stop
growing but this is often equivalent to a response as these stabilisations
may be quite durable. The role of functional imaging is becoming more
important and changes in tumour blood flow dynamics may indicate at
an early stage whether the tumour is responding. Both the imaging spe-
cialist and the oncologist have to learn how to deal with these changing
circumstances and this is best done by team working and respecting
each other’s competencies and skills. This talk will try to illustrate how
the two disciplines can work together to provide the optimal care for the
patient.
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Reduction of child mortality is one of the Millennium Development Goals;
as low- and middle- income countries (LMIC) advance towards the
achievement of this goal, initiatives aimed at reducing the burden of
non-communicable diseases, including childhood cancer, need to be de-
veloped. Approximately 185,000 children are diagnosed with cancer
every year worldwide; of those, 80 % live in LMIC, which account for
90 % of the deaths. Lack of quality population-based cancer registries in
LMIC limits our knowledge of the epidemiology of pediatric cancer; how-
ever, available information showing variations in incidence may indicate
unique interactions between environmental and genetic factors that
could provide clues to etiology. Outcome of children with cancer in LMIC
is dictated by late presentation and under diagnosis, high abandonment
rates, high prevalence of malnutrition and other co-morbidities, subopti-
mal supportive and palliative care, and limited access to curative therap-
ies. Initiatives integrating program building with education of health care
providers and research have proven to be successful in the development
of regional capacity. Intensity-graduated treatments adjusted to the local
capacity have been developed. Regional collaborative initiatives have
been developed in Central and South America and the Caribbean, Africa,
the Middle East, Asia, and Oceania. These initiatives integrate regional
capacity building, education of healthcare providers, implementation of
intensity-graduated treatments, and establishment of research programs
that are adjusted to the local capacity and needs. Together, the existing
consortia and regional networks operating in LMIC have the potential to
reach out to close to 60 % of all children with cancer worldwide. In sum-
mary, childhood cancer burden is shifted towards LMIC; global initiatives
directed at paediatric cancer care and control are urgently needed. Inter-
national partnerships facilitating step-wise processes that build capacity
while incorporating epidemiology and health services research and
implementing intensity-graduated treatments have shown to be effect-
ive. Regional networks aiming to build capacity while incorporating epi-
demiology, health-services, and outcomes research should be supported.
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sults in management dilemma because numbers of small renal
masses are either benign tumours such as angiomyolipoma (AML) or
oncocytoma, or are neoplasms with indolent behavior [1]. Surgical
treatments although provide excellent oncologic control is associated
with development and worsening of renal insufficiency and associ-
ated cardiovascular morbidity [2]. Therefore, ability to non-invasively
investigate renal tumor histopathology and aggressiveness can guide
treatment decision and lower treatment cost.
Within this paradigm, the role of radiologist and imaging is evolving
to predicting aggressiveness and biology of the tumor as well as pro-
viding operative guidance. MR imaging can play a very important
role not only as a problem solving tool, but can provide deeper
insight into tumour biology through techniques such as diffusion
weighted imaging (DWI) and perfusion weighted imaging (PWI).
Number of key observations highlighting the role of MR including
advance imaging techniques in evaluation of renal masses is as listed
below:
1. Differentiating benign renal masses from malignant tumour.
- There is some controversy regarding the role of signal loss on
opposed phase chemical shift imaging in discriminating AML from
RCC [3,4].
- Lipid poor AML tend to have uniform low T2 signal, uniform
enhancement without evidence for necrosis, and restricted dif-
fusion [5,6].
- There is overlap in the morphologic features of Oncocytoma and
RCC on conventional imaging [7, 8]. Pilot data suggests that DWI and
PWI may have a role in discriminating these benign renal tumours.
2. Histologic subtyping RCC
- Papillary subtype of RCC usually have low T2 signal, hypovascular
when compared to clear cell RCC, and have lower Apparent diffu-
sion coefficient (ADC) values. Furthermore, clear cell subtype have
heterogeneous T2 signal and demonstrate heterogeneous hyper-
vascularity [9].
- Chromophobe subtype is difficult to differentiate from clear cell
RCC on the basis of enhancement. However, advance diffusion and
perfusion MR techniques have shown some promise [10].
3. Predicting tumor aggressiveness/outcome
- Cystic RCC with less than 25 % solid enhancing component tend to
be less aggressive than solid RCC [11].
- High stage clear cell RCC tend to me more heterogeneous with
different texture compared to low stage RCC on Apparent diffusion
coefficient (ADC) map [12].
- High grade clear cell RCC tend to have lower ADC compared to low
grade clear cell RCC [13].
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Most renal tumours are currently detected incidentally on imaging
exams performed for a non-urologic indication. At the same time,
the contemporary approach to the management of renal masses has
also evolved, with additional options to the classic nephrectomy ap-
proach including nephron sparing surgery, focal therapies such as
cryoablation and the growing use of active surveillance for masses
considered unlikely to ultimately result in significant morbidity or
mortality. The role of imaging is also shifting from mere tumor detec-
tion to providing crucial information required to tailor the manage-
ment strategy to individual patients. In this session, we will discuss
the key imaging findings that need to be evaluated in patients with
renal tumours, and how they can be used to triage patients and
guide treatments.
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Adrenal:
Atypical adenomas:
Atypical large adrenal adenomas can rarely undergo degeneration
and necrosis, and cannot be distinguished from malignant tumors
and are frequently resected. It is possible that these tumours are not
FDG avid and hence could be separated from malignancies but again
they have not been studied in large enough numbers with PET-FDG
to determine this.
Fat-containing masses:
These include most often benign lesions but rarely primary malig-
nant adrenal tumours as well. Most adrenal masses containing large
amounts of macroscopic fat are adrenal myelolipomas. But there are
other uncommon adrenal masses that can contain small amounts of
macroscopic fat, such as adenomas with focal lipomatous hyperplasia
and rarely adrenal cortical carcinoma and pheochromocytoma.
Primary and metastatic lesions showing rapid washout:
There have been reports of pheochromocytomas demonstrating
rapid washout thereby mimicking adrenal adenomas. In at least two
studies of pheochromocytomas, their incidence is about 15-20 %. Inmost instances these tumours are smaller in size (<5 cms) and are
homogenous and usually biochemically active.
Metastases HCC and clear cell RCC, may demonstrate rapid washout
thereby mimicking adrenal adenomas. If there is no prior imaging,
this diagnosis could be problematic and a PET-CT or biopsy would
be needed to determine the nature of the lesion. But if there is prior
imaging, and the adrenal lesion is new or enlarging, it is likely to be
a metastasis.
Primary and metastatic lesions showing signal loss on chemical shift
(CSI) MRI:
Adrenal cortical carcinomas and pheochromocytomas may rarely
contain enough intracellular lipid to show a quantitative loss of sig-
nal intensity [SI]. Metastases from HCC and clear cell carcinoma may
contain enough intracellular lipid to cause of loss of SI on Chemical
SI MR.
Peritoneum/mesentery:
Tuberculous peritonitis:
Peritoneal disease is the most common of extra-pulmonary tubercu-
losis and is frequently associated with other forms of tuberculosis.
The imaging findings include nodular peritoneal thickening and asci-
tes. These findings may be associated with enlarged lymph nodes
and areas of GI tract involvement with the ileocecal junction being a
common site.
Sclerosing peritonitis:
Also called sclerosing “encapsulating” peritonitis, this is a rare condi-
tion seen most often in patients who are undergoing have under-
gone peritoneal dialysis. When it encapsulates abdominal organs
such as the small bowel, it is referred to as “abdominal cocoon”.
Gliomatosis peritonei:
This is a rare complication of a rupture of ovarian teratomas but can
also be seen in patients with VP shunts. On imaging, these appear as
peritoneal nodules, omental caking and ascites.
Splenosis:
Usually seen after trauma or surgery and is due to heterotopic auto-
transplantation of splenic tissue. The peritoneal nodules/masses
show similar enhancement features similar to that of splenic tissue.
Sclerosing mesenteritis/mesenteric panniculitis/mesenteric lipodystrophy
Most often the etiology is idiopathic; there is more recently an asso-
ciation found in some patients with IgG4 disorders. It has a wide
range of appearances on imaging: ranging from a proliferation of fat
to calcified soft tissue mesenteric masses.
Mesenteric Omental necrosis/fat necrosis:
In most instances, seen as fatty mass which may encapsulated with
adjacent soft tissue fat stranding. If the cause is omental torsion,
swirling vessels are seen in the adjacent vasculature. Encapsulated
fat necrosis can mimic a mass.
Fat saponification in patients with sequelae of acute pancreatitis can
lead to fat saponification and to small peritoneal nodules of fat
necrosis.
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Lung: Pulmonary nodules are commonly observed in patients with
cancer as well as in patients with no known malignancy particularly
in heavy smokers. Most of these nodules are small (less than 8 mm).
Even in cancer patients a large proportion of these small nodules are
benign [1]. The likelihood of malignancy depends on individual as-
pects (cancer type, grading, staging, molecular markers etc.), nodule
size and risk factors [1]. For example, in a heavy smoker with lung
cancer and one additional nodule larger than 8 mm the nodule is
more likely to represent a second primary than a solitary metastasis.
In a non-smoker with advanced high-grade soft-tissue sarcoma a
solitary nodule is more likely to represent a metastasis. In all cancer
patients a significant proportion of pulmonary nodules represent be-
nign lesions such as pulmonary lymph nodes or granulomas [2, 3].
Non-solid nodules (ground glass opacities) are more likely to repre-
sent lung cancer (adenocarcinoma) than solid nodules [4, 5]. How-
ever, they may represent benign lesions such as focal fibrosis or
haemorrhage. Furthermore, some (haemorrhagic) metastases may
present as non-solid nodules [6].
Consolidation or diffuse ground glass usually represents benign dis-
ease such as pneumonia. However, in adenocarcinoma with predom-
inantly lepidic growth consolidation or diffuse ground glass may be
due to cancer spread in the lung.
Pleura: Pleural effusion may be due to malignant spread (pleural car-
cinomatosis) or to several benign conditions (heart or renal failure,
haemorrhage, infection, etc.). Malignancy is usually confirmed by cy-
tologic analysis of pleura fluid. However, imaging may suggest malig-
nancy if solid pleural lesions are demonstrated within the effusion
particularly at the lung base. Unilateral effusion, particularly in the
left hemithorax or on the side of the underlying malignancy (e.g.
breast, lung cancer) also suggests malignant effusion.
Solid pleural lesions may be clearly benign such as pleural lipoma or
calcified pleural plaques in patients with asbestos exposure. Non-
calcified focal solid lesions may be benign (e.g. following infection,
haemorrhage) or malignant. Although pleural carcinomatosis is usu-
ally associated with effusion solid metastases without effusion can
occur. Diagnosis usually requires histology [7].
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Prostate cancer is the most common non-cuteaneous neoplasm in
men and the third leading cause of cancer-related death in men in
Europe.
Lymph node metastases have a significant impact on the prognosis
of patients with malignancies. Because benign and malignant lymph
nodes have similar signal intensities in conventional MR imaging
(MRI), metastatic lymph nodes are mainly identified by node enlarge-
ment. This may result in missing small metastases in normal sized
nodes, resulting in false-negative metastasis. Routine cross-sectional
imaging modalities, such as CT and conventional non-enhanced
MR imaging, have a limited sensitivity in identifying lymph node
metastases.
One of the methods to improve upon this sensitivity is the use
of lymph node specific contrast agents, such as Ferumoxtran-10:
an ultrasmall superparamagnetic iron oxide (USPIO) particle that
has proven to be a valuable contrast agent for detecting lymph
node metastases using MRI in various types of cancer (also called
nano-MRI).
After intravenous injection, USPIO particles mitigate into the intersti-
tial space, where they are incorporated in macrophages and trans-
ported to the lymph nodes. Because of the paramagnetic properties
of the iron particles contained in ferumoxtran-10, healthy lymph
nodes will feature reduced signal intensity in a T2* weighted MRI se-
quence and will appear dark in contrast. However, malignant parts of
the lymph nodes will not contain any macrophages and therefore no
iron. These lymph nodes remain high in signal intensity. Malignant
lymph nodes can therefore be detected by their high signal intensity
in strongly T2* weighted sequences [1]. A meta-analysis [2] showed a
mean sensitivity of 0.90 and a specificity of 0.96 of the USPIO parti-
cles for malignant lymph node detection.
Small metastases can be prospectively recognized in small (3-10 mm)
size lymph nodes using ferumoxtran-10-enhanced MR imaging [3].
These small lymph nodes would be considered to be benign in con-
ventional MR or CT examinations based on size criteria. In addition,
hyperplastic enlarged nodes can be correctly recognized as non
metastatic, based on maintained uptake of ferumoxtran-10. In 41 %
of patients with prostate cancer, nodal metastases outside the area
of routine pelvic lymph node dissection are detected by using nano-
MRI [4]. Furthermore, metastasis-directed therapies with salvage
radiotherapy or salvage pelvic lymph node dissection has shown
promising results in terms of biochemical recurrence-free survival
and androgen therapy-free survival [5,6].
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Background: Accurate staging and restaging of patients with pros-
tate cancer is of pivotal importance, especially when considering
loco-regional treatment of oligometastatic disease with a curative in-
tent. Next to cross-sectional and functional imaging techniques using
CT and MRI, the impact of molecular imaging has significantly in-
creased in the last years due to a number of newly developed
radiopharmaceuticals.
Radiopharmaceuticals: Now almost 20 years after the initial report
on the utility of C-11 labelled choline, a key precursor in the bio-
synthesis of phosphatidylcholine (a major component of the cell
membrane), C-11 and F-18 labelled choline-derivatives are avail-
able in many centres. Although the utility of choline PET/CT is
well-established, the limited sensitivity in low volume disease
(reflected by low PSA levels lower than 1 ng/mL) is a drawback
when assessing patients suspected of oligometastatic disease.
Prostate-Specific Membrane Antigen (PSMA), an enzyme that in
humans is encoded by the FOLH1 (folate hydrolase 1) gene, is
considered an important target for molecular imaging as PSMA is
a highly upregulated gene product in many prostate cancers.
High expression of PSMA is associated with a shorter time to pro-
gression and a higher risk for patients to relapse. Initial immu-
noSPECT experience with In-111 labelled Capromab Pendetide, a
murine, whole IgG monoclonal antibody targeting the intracellular
domain of the PSMA molecule, was and quite challenging. The
development of small PSMA-targeting molecules labelled with Ga-
68 (PSMA)or F-18 (DCFBC, DCFPyL) for PET/CT imaging was a
major step forward. Radiolabelling of the molecules is straightfor-
ward, while fast background clearance and high targeting allow
early imaging after injection of the agents. High diagnostic yields
have been reported in the lower PSA range, especially in patients
with high PSA doubling time (>85 % when PSA < 1.0 ng/ml with
PDT < 6 months).
An alternative for PSMA-based imaging agents for PET/CT is the syn-
thetic L-leucine analogue fluciclovine (FACBC), which was very re-
cently approved by the FDA. It depicts functional activity of two
different transmembrane amino acid transporters (ASCT2 and LAT1).
The distribution of the tracer in the body is favourable (negligible up-
take in the kidneys, no activity in the urinary tract) and the detection
rate of tumours seems to compare favourably to choline PET/CT
when PSA levels are low. Yet another option is F-18 labelled 5α-
dihydrotestosterone (FDHT), directly targeting the intracellular andro-
gen receptor.
Current status and future prospects: In some countries in Europe,
PSMA PET/CT has rapidly gained widespread acceptance for imaging
patients with prostate cancer. Although an overwhelming number of
favourable reports have been published recently, the definitive posi-
tioning in relation to the impact on patient management and out-
come remains to be established. With the approval of FACBC,
molecular imaging will become an available option for prostate can-
cer patients. Defining the position of all the available options for mo-
lecular imaging in the diagnostic algorithms of the various stages of
disease and convert this into guidelines are upcoming challenges.References
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Prostate cancer is a heterogenous disease where treatment is moving
towards personalised therapy. In addition to histological confirmation
and grading, imaging plays an important role in non-invasive detec-
tion, localization and staging of prostate cancer. Conventional sta-
ging such as computed tomography (CT) or magnetic resonance
imaging (MRI) and whole body bone scintigraphy (BS) are the stand-
ard of practice at primary diagnosis or relapse. However, these
modalities provide only morphological information but do not differ-
entiate the biological nature and metabolic status of the tumours,
therefore limiting its diagnostic performance.
New imaging techniques enable assessment on both structural
change as well as the underlying pathophysiology of the tumour,
thereby optimising and individualised treatment planning for pa-
tients with cancer. With the emerging data showing higher diagnos-
tic performance of the new PET tracers 18F-Fluorocholine (18F-FCH)
PET-CT and 68Galium (Ga)-PSMA PET-CT, additional options for pros-
tate cancer staging have become available [1-3]. Other functional
modalities including diffusion-weighted sequence MRI with superpar-
amagnetic iron oxide and whole body diffusion MRI, have also been
found useful in prostate cancer staging [4-5]. In addition to add-
itional staging information provided, another advantage of these
new imaging techniques over conventional staging is the ability to
detect metastases at an earlier stage where disease is smaller volume
and limited in number, namely oligometastases, thereby allowing for
potentially radical treatments to be offered whether at primary or
salvage setting.
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tecting site-specific disease. For nodal disease, both (68GA)-PSMA
and MRI with superparamagnetic iron oxide are highly sensitive
in detecting micrometastases (<2 mm) within normal size lymph
node, with the former able to achieve detection rate of 60 % at
PSA < 0.5 ng/ml [5-6]. For bony disease assessment, whole body
diffusion MRI excels in its detectability compared to conventional
staging [7]. It is also useful in assessing response to treatment,
therefore prompting change in treatment strategy for non-
responders [7]. Although (18 F-FCH) PET-CT has lower sensitivity
than 68 Ga –PSMA in detection of metastatic lesions, it was the
one of the earliest functional imaging techniques adopted in
prostate cancer management and has facilitated the application
of metastatic-directed therapy in patients with oligometastases in
the last 5 years, exploring a new treatment paradigm in the set-
ting of metastatic disease [1]. Apart from diagnostic purposes,
integrating the molecular level information obtained from these
functional imaging, particularly PET-CT may potentially lead a
pathway for therapy targeting.
The use of functional imaging in prostate cancer from staging, detec-
tion of relapse to treatment response monitoring and potential
therapeutic targets is promising, rapidly evolving, and likely to de-
liver improved outcomes for patients.
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Combining ADC-histogram features improves performance of MR
diffusion-weighted imaging for lymph node characterisation in
cervical cancer
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Cancer Imaging 2016, 16(Suppl 1):S1Aim: To evaluate whether a statistical classification combining
ADC-histogram features (apparent diffusion coefficient) (ADC)
improves lymph node characterisation in patients with cervical
cancer.
Methods: Thirteen patients with cervical cancer underwent pelvic
magnetic resonance imaging (MRI) including diffusion-weighted
imaging (DWI) with 6 b-values ranging between 0 and 1000 s/
mm2. All pelvic lymph nodes of 4 mm or greater in short axis
diameter were delineated and twelve first order statistics features
were extracted from the ADC histogram. Three features were
based on the cumulative ADC intensity-volume histogram: two
describing the volume and intensity above a certain threshold of
ADC max, and one based on area under the curve. A recursive
feature selection algorithm was used to obtain the best combin-
ation of features using histopathology after surgical sampling as
ground truth. A predictive model based on the optimal combin-
ation of features using logistic regression (LR) as classifier was
compared with conventional ADC in terms of sensitivity, specifi-
city and accuracy. This evaluation was done by nested cross val-
idation for model selection.
Results: Radiological-histopathological correlation was possible for 94
lymph nodes (26 positive and 68 negative nodes). The predictive
model combining two features: F6 (Skewness) and F3 (Median) re-
sulted in 86.00 % ± 2.54 % sensitivity, 89.47 % ± 1.47 % specificity,
and 88.51 % ± 1.77 % accuracy. In comparison, conventional ADC
mean showed 72.56 % ± 3.19 % sensitivity, 73.68 % ± 1.38 % specifi-
city and 73.37 % ± 1.88 % accuracy.
Conclusion: Classification combining two first order features ex-
tracted from the ADC-histogram of DWI MRI data improves
characterization of lymph nodes in cervical cancer compared to
conventional ADC.
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Aim: To evaluate whether whole-body diffusion-weighted mag-
netic resonance imaging (WB-DWI) is able to correctly predict
operability in patients with colorectal cancer and peritoneal
metastases.
Methods: Sixty patients diagnosed with colorectal cancer and peri-
toneal metastases underwent WB-DWI prior to laparotomy in this
prospective single centre study. The peritoneal cancer index (PCI)
was estimated on WB-DWI and compared to PCI during laparotomy.
Furthermore, presence of nodal and/or distant metastases was evalu-
ated. Histopathology after surgery or biopsy was used as primary ref-
erence standard.
Results: WB-DWI correctly predicted operability in 54 of 60 pa-
tients (90 %). In 6 patients the disease extent was underesti-
mated by WB-DWI (in 5 patients the predicted PCI was too low,
in 1 patient a periportal adenopathy was missed). In none of the
patients WB-DWI overestimated the PCI, thus none of the patients
were incorrectly deprived from surgery. Eighteen patients had
irresectable distant metastases. WB-DWI correctly identified 17 of
these 18 patients (94 %).
Conclusion: WB-DWI is a reliable staging method for surgical plan-
ning in patients with colorectal cancer and peritoneal metastases.
Our results need to be confirmed in larger studies.
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Aim: To evaluate the potential of the apparent diffusion coefficient
(ADC) in predicting extracapsular extension (≥ pT3a) of prostate can-
cer (PCa).
Materials and methods: We analysed 301 consecutive PCa patients
(137 low-risk and 164 intermediate/high-risk by EAU classification)
who underwent pre-surgical multiparametric MRI. The index lesion
was assigned a score (from 1-5) for its probability of being ≥ pT3a
based on the T2-weighted images (ECE score) and its ADC value
measured. An ADC value cut-off for predicting ≥ pT3a was obtained
from ROC analysis. Diagnostic performances of risk groups, ECE score
and ADC (best cut-off) of index lesion for predicting ≥ pT3a were cal-
culated. The effects of risk group, ECE score and ADC value (best cut-
off) for predicting ≥ pT3a were calculated on a multivariate analysis.
Results: 119 patients were ≥ pT3a and 182 patients < pT3a at surgery.
The ADC cut-off value (1031 μm2/s) showed an ability to rule out (Sensi-
tivity, negative predictive values, negative likelihood ratio) and rule in
(specificity, positive predictive value, positive likelihood ratio) ≥ pT3a re-
spectively of 85 %/86 %/0.24 and 63 %/60 %/2.27. The corresponding
values for the ECE score were 78 %/85 %/0.26 and 83 %/75 %/4.59 and
those for risk group were 76 %/80 %/0.39 to 60 %/ 55 %/1.91 respect-
ively. The addition of the ADC value to risk group and to ECE score im-
proved the ability to predict ≥ pT3a (AUC from 0.85 to 0.87; p <0.0001).
Conclusions: The index lesion ADC value showed an additional value
in predicting ≥ pT3a to risk group classification and to the standard
assessment of extracapsularity based on T2-weighted images.
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Aim: To evaluate the impact of PET/CT on clinical management in
daily routine based on a prospective data registry and to link these
information with the expected benefit on patient outcome (“linked
evidence approach”).
Methods: A prospective patient cohort (04/2013-04/2015) having a
PET/CT for oncological reasons was evaluated based on questionnaires
from referring physicians on intended management pre- and post-PET/
CT. Primary endpoint was the impact of PET/CT on management re-
garding treatment or further investigations in different indications and
cancer types. Secondary endpoint was to develop a model linking the
management changes (=intermediate outcome) with patient outcome.
Results: 2692 patients were evaluated (61 ± 15 ys, 64 % m). Lung,
prostate, melanoma, NET and lymphoma accounted for 2/3 of cases.
The most frequent PET/CT indication was staging (62 %). Overall,
physicians changed their intended management in 58 % of patients
(95 % CI, 56 %-60 %) based on PET/CT results. In 24 % of all cases
(22 % prostate, 34 % melanoma) management changed from non-
treatment (e.g. watching, additional imaging) to a post PET/CTtreatment strategy. The impact of PET/CT was highest in reducing de-
mands for additional testing. Uncertainties regarding treatment goal
(curative vs palliative) were reduced by 35 %. By linking registry data
with FU data, first in melanoma, the impact of PET/CT on outcome
could be demonstrated (RO metastasectomy).
Conclusion: Registry data confirmed that physicians often change
their intended management on the basis of PET/CT. Based on certain
assumptions the “linked evidence” approach could be used as a
model to generate evidence for the clinical benefit of PET/CT.
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Purpose: To evaluate heterogeneity of response in skeletal metasta-
ses from breast cancer with 18F-fluoride and 18F-FDG PET.
Method: Baseline and 8 week 18F-fluoride and 18F-FDG PET scans
were analysed in 8 females (mean age 65.6 years) taking part in a
multimodality treatment response study. SUVmax was measured in
up to 5 metastases in each patient (33 lesions) and EORTC PET
criteria used for response categorisation (SD, PR, PD). Clinical re-
sponse was measured up to 24 weeks by conventional biochemical
and imaging methods (bone scan, CT, pain score, biochemistry,
tumour markers).
Results: Less than half of the skeletal metastases showed concordant
response categorisation between 18F-fluoride and 18F-FDG (14/33 le-
sions) with 15/33 lesions showing minor discordance and 4/33 lesions
complete discordance. 6 patients showed interlesional response cat-
egorisation heterogeneity with 18F-fluoride and 5 with 18F-FDG, PD
and PR lesions coexisting in 2 patients in each group. In patients with
24 week clinical PR, 8/19 18F-fluoride and 11/19 18F-FDG lesions
showed PR. In those with clinical PD, 2/10 18F-fluoride and 0/10 18F-
FDG lesions showed PD. 10/13 18F-fluoride lesions in patients with a
clinical PR showed a flare at 8 weeks that reduced by 12 weeks.
Conclusion: There is significant discordance between 18F-fluoride
and 18F-FDG PET response assessment in breast cancer skeletal me-
tastases at 8 weeks. 18FDG PET is better at predicting response at
8 weeks but neither tracer can reliably predict progressive disease at
this early time point. Within individual patients there is frequent
interlesional response heterogeneity with both tracers.
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Aim: To determine if suspicious breast imaging can be used to in-
form the patients of the diagnosis of breast cancer, at first one-stop
clinic attendance.
Methods: List of breast cancers diagnosed in year 2013 was obtained
from the audit department. Radiology database and clinical portal
were used to review clinical requests and imaging. Caldicott approval
was obtained. Breast imaging results were analysed and correlated
with core biopsy results and final histopathology. For all patients
with benign imaging, radiology database was checked for 2 years to
ensure no representation with cancer. Accuracy of imaging in the
diagnosis of breast cancer and positive predictive value (PPV) of ab-
normal/suspicious imaging was calculated.
Cancer Imaging 2016, 16(Suppl 1):28 Page 23 of 34Results: Over 3800 patients had imaging in 2013. Of these, 198
patients were diagnosed with breast cancer. Imaging was indeter-
minate/suspicious/positive for malignancy in 93.4 % (185 cases)
of cases of proven malignant diagnosis. 82.3 % [n = 163] patients
had suspicious imaging with biopsy proven diagnosis of breast
cancer. There were 4 false positive cases (suspicious imaging but
benign histology). Two cases had B3 core biopsy results and
there was 1 case of parenchymal distortion. Excision was recom-
mended for all three cases. There was 1 case of peri-ductal mas-
titis, which was suspicious on radiology. PPV of suspicious
radiology for breast malignancy was 97.6 % PPV of suspicious
radiology for surgery was 99.4 %
Conclusion: Suspicious radiology (overall imaging opinion of 4 or
above) has high PPV for diagnosis of breast cancer and/or surgery.
This can be used reliably to inform the patients of their likely
diagnosis.
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Aim: To assess whether changes in semi- and fully automated mea-
sures of tumour volume between baseline and interim magnetic res-
onance imaging (MRI) are equivalent in predicting pathological
response to neoadjuvant chemotherapy (NAC) for primary breast
cancer, focusing on the accurate prediction of minimal residual
disease.
Methods: 78 patients undergoing NAC underwent contrast-enhanced
MRI before and after 3 cycles of treatment. Tumour volumes were
measured using fully- (BreVis; FTV) and semi-automated (ITK-Snap;
ETV) methods. Two-minute post-contrast subtracted images were
analysed for ETV. ETV intra- and inter-observer reproducibility was
assessed with calculation of the coefficient of reproducibility (CoR).
Percentage reduction in FTV and ETV between baseline and in-
terim MRI was compared with final pathological response using
the residual cancer burden score (RCB) on resected specimens,
and significance of any differences was assessed with Mann-
Whitney U tests.
Results: There was good correlation between ETV and FTV (r = 0.744).
Intra and inter observer CoR for ETV was 11.6 % and 14.8 % respect-
ively. Mean % reductions in ETV by pathological response were: pCR
96.4 % (n = 12), RCB-I 66.6 % (n = 10), RCB-II 62.9 % (n = 39), RCB-III
27.3 % (n = 17). Corresponding values for FTV were: 88.8 %, 70.6 %,
54.6 % and 20.8 %. Significant differences in % ETV changes were
found for pCR vs. RCB-I, II & III (all p < 0.008). For FTV, significant dif-
ferences were measured only for pCR vs. RCB-II & III (both p < 0.001).
Conclusion: ETV changes between baseline and interim MRI differen-
tiate better between pCR and minimal residual disease than FTV.
Such differentiation could facilitate novel approaches to surgical
management post NAC.
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Cancer Imaging 2016, 16(Suppl 1):S8Aims: The aim of this study was to determine the diagnostic yield of
urothelial malignancy in patients undergoing haematuria screening
with CT intravenous urography (IVU).
Methods: A retrospective study reviewed 332 consecutive patients
undergoing CT IVU at the Homerton Hospital over a six-month
period (July to December 2015. Inclusion criteria were only haema-
turia screening patients Demographic details, whether haematuria
was macroscopic or microscopic, cause for haematuria (if present),
and significant incidental findings, were recorded.
Results: A total of 256 patients met the inclusion criteria. The average
age was 59 (range 26 - 95) with 56 % (144/256) men and 44 % (112/256)
women. Of these, 52 % (132/256) had macroscopic and 44 % (113/256)
had microscopic haematuria (not recorded in 4 %). A cause for haema-
turia was determined in 14 % of patients (35/256). Malignancy was seen
in 3 % (7/256), of which bladder cancer accounted for 1.5 % (4/256) and
renal cancer for 1.2 % (3/256). No ureteric malignancy was detected. A
malignant cause for macroscopic haematuria was seen in 4 % (5/132)
and for microscopic haematuria in 2 % (2/113) patients. Renal tract calculi
accounted for haematuria in the remaining 11 % (28/256).
Conclusion: The results demonstrate likely overuse of CT IVU with
low diagnostic yield in haematuria screening. With only 14 % demon-
strating a cause and no ureteric malignancy evident, better resource
management is seemingly possible. No current consensus guidelines
are available and, after review of current literature, we recommend
the use of stricter criteria for imaging.
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Aims: The objective of this study was to evaluate the efficacy of percu-
taneous radiofrequency ablation of locally advanced pancreatic cancer
located in the pancreatic body.
Materials and Methods: Patients with biopsy-proven locally ad-
vanced pancreatic adenocarcinoma were considered for percutan-
eous radiofrequency ablation. Post-procedural CT studies and Ca19.9
tumour marker evaluation were performed at 24 hours and 1 month.
At CT treatment effect was evaluated excluding the presence of com-
plications. The technical success of the procedure is defined at CT as
the achievement of tumoural ablated area.
Results: 23 patients have been included in the study. 5/23 of the pa-
tients were excluded. At CT the mean size of the intra-lesional post-
ablation necrotic area was 32 mm (range 15 – 65 mm). Technical suc-
cess of the procedure has been obtained in (16/18) 93 % of cases.
None of the patients developed post-procedural complications. Mean
Ca19.9 serum levels one day before, one day after and one month
after the procedure were respectively 285,8 U/ml (range 16,6–942,0
U/ml), 635,2 U/ml (range 17,9–3368,0 U/ml) and 336,0 U/ml (range
7,0–1400,0 U/ml). Follow-up duration was less than 6 months for 11
patients, more than 6 months for 7 patients. At the time of the draft
of this paper, the mean survival of the patients included in the study
was 185 days (range 62–398 days).
Conclusion: Percutaneous radiofrequency ablation of locally ad-
vanced adenocarcinoma has an high technical success rate and is ef-
fective in cytoreduction both at imaging and laboratory controls.
S10
Iodine maps from dual energy CT improve detection of metastases
in staging examinations of melanoma patients
M. Uhrig, D. Simons, H. Schlemmer
German Cancer Research Center Heidelberg, Germany
Correspondence: M. Uhrig (m.uhrig@dkfz.de) – German Cancer
Research Center Heidelberg, Germany
Cancer Imaging 2016, 16(Suppl 1):S10
Cancer Imaging 2016, 16(Suppl 1):28 Page 24 of 34Aim: Staging of melanoma patients by CT is challenging, because
metastases may hide in every part of the body and can exhibit a
similar density to some body own tissues, e.g. musculature. Iodine
maps (IM) from dual energy CT (DECT) highlight enhancing lesions
and visualise their spatial contrast medium distribution. Purpose of
this study was to evaluate whether IM improve lesion detection in
staging examinations of melanoma patients.
Methods: 75 DECT scans (thorax (T) and abdomen (A)) from 75 mel-
anoma patients were retrospectively analyzed. For each patient 3
conventional image reconstructions (cCT) (T: lung kernel 1 mm axial
and soft tissue kernel 3 mm axial, A: soft tissue kernel 3 mm axial) as
well as 3 IM (T: 1 mm and 3 mm axial, A: 3 mm axial) were provided.
A radiologist reported the number of lesions detected additionally by
analysing the IM following cCT.
Results: Total 44 lesions (17 metastases) in 29 patients were addition-
ally detected on IM. All lesions could retrospectively be identified on
cCT and were located in the liver (34 %), inter or intramuscular
(23 %), subcutaneous (9 %), lung (7 %), mesenterial (5 %), intestinal
(5 %), mediastinal (5 %), skeleton (4 %), pancreas (2 %), vagina (2 %),
supraclavicular (2 %) and peritoneal (2 %). Lung findings included 2
pulmonary emboli.
Conclusion: IM from DECT improve detection of metastases and
relevant secondary findings in staging examinations of melanoma
patients.
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Aim: At our institution iliac lymph node (LN) dissection for melanoma
is often performed concurrently with inguinal LN dissection. If CT can
accurately stage pelvic lymph nodes above the inguinal ligament a
subset of patients may be spared iliac node dissection and its associ-
ated morbidity. We evaluate the accuracy of CT in LN staging and
the predictive value of individual CT imaging features of inguinal and
pelvic LN metastases using histology as a gold standard.
Method: In a retrospective analysis of 92 consecutive patients, LN
characteristics on CT; size, a rounded morphology, the presence of
extracapsular spread, abnormal contrast enhancement, cortical nodu-
larity and a fatty hilum, within the inguinal, cloquet, external iliac,
side-wall, common iliac and para-aortic LN groups were compared to
histology (Fishers exact test).
Results: LN size on CT was predictive of pathological involvement
(p < 0.001) although a rounded morphology was not. The sensitiv-
ity of extracapsular spread within the inguinal LN group was high
(100 %, p = 0.52) and predictive of pelvic LN spread (p = 0.009).
CT was sensitive for inguinal and common iliac (100 %) as well
as external iliac (83 %) but less sensitive for cloquet (67 %) and
side-wall involvement (67 %). The presence of cortical nodularity
or the absence of a fatty hilum were not helpful.
Conclusion: CT can help predict pelvic nodal status in patients with ma-
lignant melanoma of the lower limb and the presence of extracapsular
spread in inguinal LN group is suggestive of more proximal disease.
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Aim: To assess the positive yield for malignancy in imaging investiga-
tions for suspected paraneoplastic neurological syndrome.Method: Study performed in Institute of Neurological Sciences, a
tertiary neurological centre serving 2.7 million in the west of
Scotland. Obtained list of all inpatients who had a CT Chest ab-
domen and pelvis (CT CAP) done for suspected PNS over a
16 month period. Case notes, clinic letters, other imaging inves-
tigations and autoantibody tests were retrospectively reviewed.
Patients’ initial neurological symptoms, ultimate neurological
diagnosis and presence of a malignancy after a minimum of 1-
year follow-up were recorded.
Results: 75 patients had a CT for suspected PNS (Excluding myas-
thenia gravis), 16 of which had follow-up PET-CT, 3 Mammo-
grams, 5 Testicular ultrasounds and 6 repeat CT CAP. Only three
relevant tumours detected (4 %), two on initial CT CAP and one
on subsequent PET-CT. One incidental breast cancer found, unre-
lated to patient’s neurology. Only two of those with no cancer
detected after one-year follow-up are still suspected to be para-
neoplastic, with the remaining 69 cases given an alternative
neurological diagnosis.
Conclusion: There is very little in literature on expected positive yield
of malignancy for suspected PNS. However, our study found the yield
to be very small. Many of those scanned had nonspecific neurology
rather than recognised PNS. Given the significant amount of radi-
ation involved, we felt there is a need for an agreed guideline on
which patients should be investigated.Poster presentations
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Aim: To analyse the technical success of ablation therapy and
the incidence of complications in patients treated with pulmon-
ary ablation at a District General Hospital without on-site
cardiothoracic support. This poster will present the complication
profile in this patient group. Management of complications will
be discussed.
Materials and methods: Technical success and complications in all
patients undergoing lung ablation between June 2009 and July 2015
was recorded. Ablation was performed under deep conscious sed-
ation according to standard protocols.
Results: 207 pulmonary ablations were performed in 86 patients at
156 attendances. A variety of tumour types were treated.
Technical success was achieved in 207/207 (100 %).
 30 and 90 day mortality was 0 %.
 35/86 (40.7 %) patients were treated as day cases. None were
readmitted.
 84/86 (97.7 %) patients were discharged within 24 hours of the
ablation.
The major complication (pneumothorax requiring chest drain, severe
chest pain and symptomatic pseudoaneurysm) rate was 13/86 (15 %).
 2/86 (2.3 %) patients developed psuedoaneurysms.
 15/86 (17.4 %) patients had a significant pneumothorax.
 6/86 (7.0 %) patients required a chest drain.
 6/86 (7.0 %) patients described significant chest pain.
 1/86 (1.1 %) developed an asymptomatic rib fracture.
Conclusion: RFA is a safe and effective procedure that can be per-
formed without on-site cardiothoracic support.
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Aim: to assess factors affecting local disease control and patient sur-
vival in patients with pulmonary metastases from colorectal cancer
treated with percutaneous radiofrequency ablation.
Methods: Using a prospective database overall survival and local
disease control was calculated.
Factors influencing outcome were explored.
Results: 101 pulmonary metastases were treated in 46 patients.
 An average of 2.2 lesions per patient (range 1 to 8).
 The median diameter was 9 mm (range 3-29 mm).
 18 (40.9 %) had bilateral metastases.
 13 (29.5 %) had extrapulmonary metastatic disease.
Mean survival time of 53.58 +/- SE3.47 months with a 1, 2, 3, 4 and
5 year survival of 97.4 %, 91.3 %, 81.5 %, 59.8 % and 48.0 %.
There was no statistically significant difference in survival with
regards to:
 time to development of metastatic disease.
 the total number of lesions ablated.
 the initial number of lesions ablated.
 the maximum size of lesion treated.
 unilateral vs bilateral disease.
Patients with extra-pulmonary disease had a shorter survival from
primary diagnosis.
23 (22.8 %) of the 101 lesions were found to have progressed after
first RFA. The mean time to recurrence was 9.6 +/- SD7.7 months
(median 8 months, range 1 – 38 months).
 The mean initial size of the progressed lesions was greater
than the mean initial size of the stable lesions p = 0.002.
 Local relapse was more likely when a metastases was close to
a large (>3 mm) vessel (p = 0.002).
Conclusion: Ablation of pulmonary metastases in selected patients
can improve patient outcome. Lesion size and proximity to large ves-
sels are important considerations when planning treatment.
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Aim: We describe a case study that demonstrates radiology can cor-
rectly predict a malignant process in a mass forming infectious clin-
ical background.
Methods: We analysed clinical findings of a 34 year old male
patient who had successfully completed treatment for pulmon-
ary TB with suspected multisytemic relapse. Chest radiograph,
chest and head CT scans were ordered. Tissue diagnosis of an
easily accessible intracranial lesion was done on radiological
recommendation.Results: A large right occipital lobe mass and other satellite smaller
lesions within the contralateral frontal lobe were seen on the cranial
CT. In the chest right apical findings consistent with post-TB changes
and bilateral multiple rounded opacities within the lung parenchyma
were seen. An irregular mass within the visualised right liver lobe
was also noted. Pre-contrast images had attenuation indicating
haemorrhage within the lesions. These features strongly suggested a
radiological diagnosis of metastatic disease rather than TB from our
experience. Histologic diagnosis of the large brain lesion was a malig-
nant epithelial tumour with high vascularity and necrosis. Immuno-
histochemistry tested positive for hepatocyte paraffin (Hep Par 1)
and cytokeratin AE1/AE3 antibodies. Clinical and serological findings
had not depicted higher risk for HCC.
Conclusion: In tropical Africa mass forming infectious diseases are very
common radiological findings. Radiologists must be knowledgeable of
the patterns that are more predictive of a malignant lesion even when
the clinical information suggests an infective process.
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Aim: To evaluate the potential of the apparent diffusion coefficient
(ADC) in predicting extracapsular extension (≥ pT3a) of prostate can-
cer (PCa).
Materials and methods: We analysed 301 consecutive PCa patients
(137 low-risk and 164 intermediate/high-risk by EAU classification)
who underwent pre-surgical multiparametric MRI. The index lesion
was assigned a score (from 1-5) for its probability of being ≥ pT3a
based on the T2-weighted images (ECE score) and its ADC value
measured. An ADC value cut-off for predicting ≥ pT3a was obtained
from ROC analysis. Diagnostic performances of risk groups, ECE score
and ADC (best cut-off) of index lesion for predicting ≥ pT3a were cal-
culated. The effects of risk group, ECE score and ADC value (best cut-
off) for predicting ≥ pT3a were calculated on a multivariate analysis.
Results: 119 patients were ≥ pT3a and 182 patients < pT3a at surgery.
The ADC cut-off value (1031 μm2/s) showed an ability to rule out
(Sensitivity, negative predictive values, negative likelihood ratio) and
rule in (specificity, positive predictive value, positive likelihood ra-
tio) ≥ pT3a respectively of 85 %/ 86 %/ 0.24 and 63 %/ 60 %/2.27.
The corresponding values for the ECE score were 78 %/ 85 %/ 0.26
and 83 %/ 75 %/ 4.59 and those for risk group were 76 %/ 80 %/
0.39 to 60 %/ 55 %/1.91 respectively. The addition of the ADC value
to risk group and to ECE score improved the ability to predict ≥ pT3a
(AUC from 0.85 to 0.87; p <0.0001).
Conclusions: The index lesion ADC value showed an additional value
in predicting ≥ pT3a to risk group classification and to the standard
assessment of extracapsularity based on T2-weighted images.
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Aim: To audit and compare the change in lung cancer histopath-
ology and biopsy practice over a decade in a Glasgow hospital
with reference to the standards set by the British Thoracic
Society.
Cancer Imaging 2016, 16(Suppl 1):28 Page 26 of 34Materials and methods: All the lung biopsies performed in the west
of Glasgow in 2005 and 2015 were analysed looking at patient
demographics, lesion characteristics, complication rates and sample
histopathology. The results for 2005 and 2015 were compared to
each other to assess change in tumour type and clinical practice
audited against the current BTS guidelines.
Results: 89 lung biopsies were carried out in 2005 and 106 in 2015. We
found that there was a rise in the incidence of adenocarcinoma and a
decrease in incidence of small cell carcinoma. The mean lesion size had
decreased, depth from the skin increased and there was a marked in-
crease in the percentage of biopsied lesions measuring 1 cm or less
(2 % to 32 %). The complication rate for both years was within the ref-
erence standard set by the BTS and showed little interval change.
Conclusions: In our population we have shown over 10 years a shift
in cancer histopathology, with a rise in pulmonary adenocarcinoma.
We found a trend to performing biopsies on smaller and deeper le-
sions. This may be due to earlier cancer detection, and a greater
push from clinicians to obtain definitive histology.
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Aim: Solid pseudopapillary tumour of the pancreas is a rare exocrine
tumour with low malignant potential accounting for 0.2-2.7 % of all
primary pancreatic neoplasms. It is frequently asymptomatic and usu-
ally detected when it has grown to a large size.
It is typically seen on imaging as a well-encapsulated mass with varying
solid and cystic components caused by hemorrhagic degeneration.
Calcifications and enhancing solid areas may present at the periphery
of the mass. It usually located in the pancreatic body and tail. We
aim to describe imaging findings in patients with pathologically-
confirmed solid pseudopapillary tumour of the pancreas.
Methods: 6 patients with pathologically-confirmed solid pseudopapil-
lary tumour of the pancreas from 4 institutions in Singapore within
the last 5 years were reviewed. There were 1 male and 5 females
with age range from 9 to 62 years. Multiphasic CT for all 6 cases and
multiphasic MRI for 1case were performed.
Results: 3 patients were asymptomatic and the other 3 presented
with abdominal pain. Imaging patterns were well-encapsulated mass
(5 cases), ill-defined mass with extracapsular invasion (1 case), hypo-
dense mass with varying solid and cystic component (all 6 cases),
peripheral calcification (2 cases), enhancing peripheral solid compo-
nent (all 6 cases), located in body or tail (all 6 cases).
Conclusion: Most of our cases showed typical appearances with
some atypical imaging features. Recognising their imaging features
will help early diagnosis.
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Introduction: Colon cancer represents the fourth leading cause of
cancer death worldwide. In recent years, medical practice has started
implementing the concept of “Locally advanced colon cancer" for
cancer patients with T3, T4 or N positive.
Since neo-adjuvant therapy was proven beneficial in cases of other
locally advanced tumours, the question of whether it could also
benefit patients with locally advanced colon cancer has arisen.Objectives: Determine whether preoperative staging with MDCT can
predict the TN stage of the disease.
Materials and methods: We included 39 MDCT of patients who went
through a primary colon tumour resection during the 2013-2016
period.
Patients with visible metastases were excluded. The preoperative CT
scans were reviewed independently by two radiologists who were
unaware of the histological stage.
Results: The observer A correctly predicted 64 % of cases for T and
46 % for the N stages. The observer B predicted 56 % for T and 12 %
for N stages.
The agreement between observers for the prognostic stage was
66 % for T and 4 % for N. Both observers agreed among themselves
and with the final pathology in 51 % and 5 % of cases for T and N,
respectively.
Conclusion: MDCT is an accurate method for staging pre-surgical
colorectal cancer patients. The diagnostic yield is particularly high in
the identification T stage becoming lower in N staging, where
greater variability between observers is obtained. Recognising locally-
advanced-tumours in the preoperative.
P8
Image guided biopsy of thoracic masses and reduction of
pneumothorax risk: 25 years experience
B K Choudhury, K Bujarbarua, G Barman
Dr. B. Borooah Cancer Institute, Guwahati, India
Correspondence: B K Choudhury (bkchoudhury@gmail.com) – Dr. B.
Borooah Cancer Institute, Guwahati, India
Cancer Imaging 2016, 16(Suppl 1):P8
Aim: The purpose of our study was to determine accuracy and reli-
ability of image guided thoracic biopsy and to know the efficacy of
uses of different measures to reduce the risk of pneumothorax.
Materials and methods: Fine needle aspiration biopsies were per-
formed in 1650 patients from 1989 to 2014 using Fluoroscopy, Ultra-
sound and CT as Image guidance. After reviewing the patient, chest
skiagram, CT and coagulation profile an appropriate plan was formu-
lated for safest approach to the lesion by a fine needle. Several mea-
sures were applied to reduce the risk of pneumothorax. Immediately
after the procedure puncture site was put on dependant position.
Other measures included accurate and careful manipulation of nee-
dle, extra pleural approach, widening of extrapleural space, pathway
through non-aerated lung, use of small bore needle etc. All patients
underwent chest radiography to detect a pneumothorax.
Results: Fluoroscopy, US and CT as guidance were used in 170
(10.30 %), 270 (16.36 %) and 1210 (73.33 %) cases respectively.
Results obtained in 1419 cases (86 %). Malignant cases were
1078 (76 %). Common complication was pneumothorax and oc-
curred in 38 cases (2.3 %). Only three cases required placement
of a chest tube, rest were small and resolved spontaneously. Inci-
dence of pneumothorax dropped significantly after using several
measures.
Conclusion: Image guided biopsy is a safe and reliable method in tis-
sue diagnosis of thoracic lesions with low morbidity and high accur-
acy. Most common complication is pneumothorax. Pneumothorax
can be significantly reduced by meticulous planning using several
measures.
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Cancer Imaging 2016, 16(Suppl 1):28 Page 27 of 34Purpose: 18F-FDG PET texture analysis (TA) provides a measure of
tumour heterogeneity but it is unknown if it can differentiate benign
and malignant peripheral nerve sheath tumours (PNSTs) in patients
with neurofibromatosis-1, a frequent diagnostic dilemma. We com-
pared TA with maximum standardised uptake value (SUVmax) in 18F-
FDG PET for this purpose.
Methods: 18F-FDG PET was performed at 90 and 240mins post-
injection in 55 patients with neurofibromatosis-1 and suspected ma-
lignant transformation (M:F 30:25, mean age 34.9 years). All patients
had a histological reference standard. TA was performed at both
time-points measuring 1st, 2nd, high-order and model-based texture
parameters. Statistical comparisons were made using ROC analysis.
Results: 31 benign and 24 malignant lesions were confirmed histo-
pathologically. AUROC was greatest for SUVmax at 90 and 240 min
time-points (0.991, 3 false-positives and 0.996, 2 false-positives, re-
spectively). Standard deviation (SD), entropy, fractal dimension (FD)
and coarseness performed well (0.965, 0.991; 0.942, 0.952; 0.804, 0.81;
0.890, 0.891). The greatest AUROC resulted from the combined par-
ameter SUVmax/FD (0.997, 0.996) with only one false positive result
and no false negatives.
Conclusions: TA does not improve discrimination of benign and ma-
lignant PNSTs further compared to SUVmax. However, a number of
texture features measuring tumour heterogeneity show good dis-
crimination and using a combined parameter (SUVmax/FD) maxi-
mises diagnostic accuracy.
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Aim: Prior to the introduction of VAE, diagnostic surgical excision
was required for high risk (B3) breast lesions. Our aim was to find if
the introduction of VAE reduced the number of diagnostic surgical
excision biopsies in our unit.
Methods: We conducted an audit over a one year period, Feb 2015
to Jan 2016, at our institution. From our records we identified all pa-
tients with B3 or B4 diagnosis in the initial (10G or 14G) biopsy who
then went on to have 7G VAE or diagnostic surgical excision
biopsies.
Results: 21 patients in the breast screening programme were identi-
fied to have B3 or B4 lesions. 18 of these patients had VAE and 3
had diagnostic surgical excision. Of these 3, the first patient declined
VAE, the second patient opted for therapeutic surgery without fur-
ther biopsy and the procedure was unsuccessful in the third patient
due to technical difficulty.
Of the 18 cases that had VAE, three cases were upgraded to B5 and
underwent therapeutic surgery. Eight cases were downgraded to B2
and seven cases remained B3. Therefore we avoided surgery in 15
out of 21 patients.
Our study demonstrates that 7G VAE has reduced the number of
diagnostic surgeries for high risk breast lesions. The number of refer-
rals to the regional centre for the procedure has also reduced since
the availability of the equipment and expertise at our local unit.
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Cancer Imaging 2016, 16(Suppl 1):P11Aim: To reduce prevalent recall rate and unnecessary false positive
assessments using risk stratification scoring system.
Materials-methods: Retrospective review of 2013-2014 local screen-
ing database. Number of women at assessment clinics, initial
mammographic concern (R3-probably benign, R3-indeterminate, R4-
suspicious and R5-malignant), numbers of biopsies and surgical refer-
rals were recorded and the recall Positive Predictive Value (PPV) for
each category was calculated.
Results: 2965 women attended the assessment clinic (43 % prevalent
round). Prevalent recall rate was 10.3 %, with PPV of recall being
9.6 % compared to 25 % on the incident screen.
10.6 % of mammograms were categorised as R3-probably benign
with low PPV of recall at 1.6 %.
Largest subgroup was of patients with R3-indeterminate mam-
mograms [74.9 %]. PPV for recall in this subgroup is low at
9.5 % which drops to 4.4 % for the prevalent screen. Biopsy
rate was 25.3 % and prevalent screeners were more likely to
have benign biopsies.
Specificity was high for R4/R5 scores with combined PPV of 76.7 %
which increases to 93.6 % for R5 score. No significant variation within
this group was noted between incident and prevalent rounds.
If patient recall was limited to R4/R5 lesions on the prevalent screens,
we would have missed 8.6 % of malignancies (47cases). If patient re-
call was limited to R3-indeterminate and above, our recall rate would
have dropped to 7.8 % and potentially 0.4 % of cancers would have
been missed (2 cases).
Conclusion: Use of risk stratification scoring system can help reduce
prevalent recall rate. This may however, have a negative impact on
the cancer detection rate.
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Aim: To identify mammographic lesions with low PPV on the preva-
lent screen to decrease false-positive assessment.
Methods: The recall rate for 2013-2014 and assessment data for
March 2014 were obtained from the local database. Type of mammo-
graphic lesion and final outcome were compared.
Results: The prevalent recall rate at our unit is 10.3 %. 270 women
were assessed in one month. Symptomatic recalls and recalls for axil-
lary lymph-nodes were excluded (n = 26). Of the remaining 244 cases,
107 were prevalent screeners.
Asymmetric densities accounted for 40 % of the assessment clinic
workload (50 % on prevalent screen, 32 % on incident screen), with
low PPV of 15.9 %. In the prevalent group, no malignancy was
diagnosed.
Well-defined opacities accounted for 25 % of the assessment clinic
workload, with a very low PPV of 6.4 % (4 % prevalent round, 8.1 %
incident round).
Ill-defined opacities and parenchymal distortion are two subgroups
with high PPV of 58 % for malignancy and/or surgical referral. On the
prevalent round, PPV is 28.6 % for ill-defined opacities and 25 % for
distortions. On the incident round, PPV is 62.9 % for ill-defined opaci-
ties and 75 % for distortions.
Micro-calcifications accounted for 15.6 % of the cases recalled.
86.8 % of these were biopsied, with PPV of 28.9 % for malig-
nancy (no significant difference between the incident and
prevalent rounds).
Conclusion: Well-defined opacities and asymmetric densities are
mammographic findings with low PPV for malignancy. It is feasible
to reduce the prevalent recall rate at our centre by not recalling
these mammographic lesions, without any detrimental effect on the
cancer detection rate.
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Aim: Identifying a clinically unsuspected pulmonary embolism (UPE)
on CT is a common occurrence in oncology patients. This study
evaluates the behaviour of untreated UPE by reviewing the change
in imaging appearances with time.
Materials and methods: Between March 2010 and March 2012, 108 on-
cology patients had clinically UPE identified on CT chest imaging. Retrospect-
ive review was performed; looking for pre-existing unreported pulmonary
thrombus on prior CT, comparing changes in imaging appearances.
Results: 91 patients with incidental UPE had relevant previous CT
chest imaging. The prevalence of pre-existing pulmonary thrombi
was 13 % (n = 12). In two (17 %) of these patients pre-existing
thrombi were located in the lobar arteries and in 10 (83 %) in seg-
mental and sub-segmental branches.
Comparison of the distribution of UPE in baseline and previous im-
aging showed that in six (50 %) cases it had remained similar for a
median of 92 days (range: 63–253), in three (25 %) there was pro-
gressive extent of thrombosis (scan intervals: 84, 174, 193 days re-
spectively) and in three (25 %) distributions of thrombi were
different (scan intervals: 51,232, 547 days respectively).
Conclusions: Untreated UPE in oncology patients does not always
progress in the immediate term, with the majority in this cohort
remaining static. Resolution and variable vascular distribution sug-
gests that pulmonary thrombus can develop locally rather than as
the consequence of a thromboembolic event.
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Aims: To evaluate the feasibility of a one-stop lymph node core
biopsy service based on recent experience.
Methods: Retrospective review of all patients referred by haematol-
ogy to a single radiologist for ultrasound guided core biopsy over
17 months. Data on turnaround time, prior imaging, indication, bi-
opsy site and histological outcome recorded.
Results: 74 consecutive haematology referrals directly to a specific
radiologist for nodal biopsy from November 2014 to April 2016.
Steady increase in referrals over the 17 months. Ultrasound guided
14G core biopsy used in virtually all cases; 14G × 5 cores for ‘new
diagnoses’ and 14G × 3 for ‘relapse/transformation’.
53/74 patients (71 %) were biopsied within a week of referral, 69/74
patients (93 %) biopsied within two weeks. Most 62/74 patients
(84 %) had relevant diagnostic imaging prior to biopsy. 41/74 (55 %)
patients referred as a ‘new diagnosis’ and 33/74 (46 %) for ‘relapse/
transformation’. Biopsy sites: axilla > cervical > inguinal nodes.
Histological outcomes: 58 malignant and 16 benign. 53 haematological
malignancies including 2 patients having an excision biopsy for confirm-
ation (both T cell lymphomas). 5 non-haematological malignancies. 16
benign, of which 5 underwent another test/repeat biopsy: 3 upgraded to
malignant. Overall, >95 % diagnostic on the first US guided core biopsy.
Conclusion: US guided core biopsy provides an effective diagnosis of
haematological malignancy. Radiological considerations for a one-stop
service include: providing either ad hoc ultrasound slots or a dedicated
list; number of radiologists to support the service; considering coordinat-
ing biopsy slots with CT staging appointments; and anticipating referrals
from other MDMs should the service show promise.P15
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So Learning objectives
The International Association for the Study of Lung Cancer recently
proposed changes to the TNM Classification for Lung Cancer in order
to better align with patient prognosis. The changes will be incorpo-
rated into the 8th edition classification system, taking effect in Janu-
ary 2017. The object of this poster is to describe these changes and
illustrate them with imaging examples.
Content organisation:
T stage changes:
Greater emphasis on primary tumour size, recognising the correlation
between size and prognosis. Lower T subcategories will be desig-
nated using 1 cm size increments, and larger tumours will be shifted
into higher T subcategories.
T1a ≤ 1 cm
T1b > 1 – 2 cm
T1c > 2 – 3 cm
T2a > 3 – 4 cm
T2b > 4 – 5 cm
T3 > 5 – 7 cm
T4 > 7 cm
T2 category will include:
 Involvement of the main bronchus, regardless of distance from
the carina (without carinal involvement).
 Associated post-obstructive atelectasis/pneumonitis that extends
to the hilar region, involving either part or the entire lung.
T4 category will include diaphragmatic invasion.
N stage changes: none.
M stage changes:
 M1b Single extrathoracic metastasis in a single organ.
 M1c Multiple extrathoracic metastases in one or several organs.
Stage Groupings changes:
 New subcategories in Stages I, II and III based on T1
subcategories.
 New stage IIIC including higher T stage tumours (T3, T4) and
N3 nodal involvement.
 New subcategories in Stage IV based on M1 subcategory.
Conclusion:
Radiologists need to be familiar with the staging changes in order to be
informed and integral members of multidisciplinary patient care teams.
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Learning objectives: To review the response evaluation of immuno-
therapeutic agents with the immune – related Response Criteria
(irRC), advances made since their implementation and potential im-
aging pitfalls that derive from their differences.
Cancer Imaging 2016, 16(Suppl 1):28 Page 29 of 34Content organisation: Recent developments in anti-cancer therapies
had created the need to think of new response evaluation tech-
niques, as past criteria did not explain nor completely correlate with
all clinical tumour responses.
We would like to show an iconografic review of irRC applied to our
patients, including new developments and progress published to
date since their creation in 2009.
We will remember the potential pitfalls in imaging evaluation of
these rather new therapies and how to manage them.
Conclusions: Imaging rests as one of the most important evaluation
pillars for all anti-cancer therapies, and the use of irRC helps monitor-
ing new types of response that correlate better with clinical re-
sponses that result from the use of these new immune agents,
avoiding that way potential pitfalls that arise from the use of prior
classic response criteria.
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Learning objectives: To review the protean tumour manifestations of
succinate dehydrogenase (SDH) gene complex mutations through
multi-modality imaging techniques.
Content organisation: Mutations in the SDH gene complex are
linked to an increased incidence of a spectrum of tumours, namely
paragangliomas, and recently demonstrated strong links to other tu-
mours including gastrointestinal stromal tumours (GISTs) and renal
cell carcinomas. These mutations and their associated syndromes
have been documented in the last 15 years but the process of
tumourigenesis is still incompletely understood and the phenotypic
expression and its penetrance remains unpredictable. Advances in
medical genetics have allowed easier and earlier recognition of these
mutations, with imaging playing a major role in primary diagnosis,
screening and surveillance.
We analysed patients with SDH mutations referred to our institution
over the last decade to:
 Review the genetic basis of SDH mutations, including the
current theories behind tumourigenesis.
 Highlight the variety of clinical presentations that lead to a
specialist and tertiary centre referral.
 Present a multi-modality imaging review of the variety of
tumours and their distribution within each SDH mutation,
highlighting any differences between sporadic and syndrome-
related tumours.
 Explain surgical and medical management challenges that are
encountered when tumours manifest.
 Present our current screening and surveillance programmes for
these patients.
Conclusions: SDH mutations are associated with an early and life-
long risk of tumour development. The spectrum of tumours and their
currently unpredictable pattern of disease present complex chal-
lenges for clinical teams, and Radiologists play a vital and increas-
ingly significant role.
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Cancer Imaging 2016, 16(Suppl 1):P18Learning objectives: The purpose of this review is to describe advan-
tages of Dual Energy technique in tumour detection and lesion
characterisation.
Content organisation: Dual energy is an innovative imaging tech-
nique that has been described to have a considerable effect on the
care of oncological patients. It operates applying two different en-
ergy settings that makes it possible to differentiate materials with dif-
ferent molecular compositions on the basis of their attenuation
profiles.
We will describe the physics behind Dual Energy CT technique and
the reconstruction techniques including iodine maps, virtual unen-
hanced and monochrome virtual images. We will review 65 cases of
patients in our institution performed with a 320-row detector CT
scanner (Aquilion One, Toshiba medical systems, Otawara, Japan), be-
tween January 2014 and January 2016.
We will discuss the following pathologies:
a) Hepatocellular carcinoma.
b) Primary renal and pancreatic malignant tumours.
c) Hypervascular tumour metastasis.
Conclusion: Dual energy is an innovative imaging technique that has a
considerable effect on the care of oncologic patients. In 10 % of our pa-
tients, included in our initial database, we found that this tool improved
lesion detection in hypervascular masses. Therefore helping define a
more accurate oncological staging in these patients. Dual Energy im-
proved lesion conspicuity in all patients with hepatocellular carcinoma,
including one patient whose lesion was only visible in the iodine map.
In addition surgical planning was modified in 3 %.
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Learning objectives: To review the clinical and radiological features
of a Richter’s Transformation in Chronic Lymphocytic Leukaemia[CLL].
Content organisation: In patients with CLL a Richter’s transformation
to a diffuse large B cell Lymphoma is a serious complication occur-
ring in 5-10 % of patients. Even with treatment patient’s median
survival is only approximately 6 months. Therefore it is very import-
ant the radiologist is aware of this condition which is the purpose of
review.
We present the common clinical symptoms and signs associated with
the condition.
Also we discuss the common radiological findings of this condition
with supporting clinical examples from our institution. In particular
we describe how rapidly enlarging lymphadenopathy and extranodal
disease in CLL patients should alert the radiologist to a different
pathology such as a Richter’s Transformation.
The role of percutaneous biopsy to confirm the diagnosis and further
imaging with PET-CT will also be described.
Conclusion: The purpose of this review is to describe the clinical and
radiological features of the serious complication of a Richter’s trans-
formation in CLL patients.
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Body diffusion-weighted MRI in oncologic practice: truths, tricks
and tips
M. Nazar, M. Wirtz, MD. Pascuzzi, F. Troncoso, F. Saguier,
EP. Eyheremendy
Deutsches Hospital, Buenos Aires, Argentina
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Cancer Imaging 2016, 16(Suppl 1):28 Page 30 of 34Learning objectives: Describe the basics concepts of diffusion-
weighted imaging (DWI) and list the common indications in oncol-
ogy and applications of a DWI sequences. Discuss DW MR changes in
response to therapy and how this can be assessed. We also include
common tips and tricks to optimise quality and to avoid common
mistakes in oncology practice.
Content organisation: We will present the spectrum of tumours im-
aging and discuss:
 MRI techniques: In addition to axial acquired DWI (b value: 0,
200, 400 and 800), conventional T1w, T2w and STIR images
were usually obtained in axial and coronal planes.
 Clinical applications for oncology DW-MRI: Lesion detection,
characterisation, and response assessment.
 Image interpretation: disease is identified as areas of impeded
diffusion, however DWI findings are not specific for malignancy
because other cellular processes, such as inflammation can
result in similar findings.
We will review:
 False - positive results.
 False - negative results.
Conclusion: DWI can be clinically useful for tumour detection, lesion
characterisation, and therapy response. A correct technique and know-
ledge of potential interpretative pitfalls will help to avoid mistakes.
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D.J. Quint, L. Dang, M. Carlson, S. Leber, F. Silverstein
University of Michigan Medical Center, Ann Arbor, Michigan, USA
Correspondence: D.J. Quint (djquint@umich.edu) – University of
Michigan Medical Center, Ann Arbor, Michigan, USA
Cancer Imaging 2016, 16(Suppl 1):P21
Learning objectives: In paediatric patients with Acute Lymphoblastic
Leukemia (ALL) being treated with intrathecal methotrexate, we will
review the:
a) prevalence and breadth of subacute neurologic symptoms.
b) MRI findings with special emphasis on diffusion MR.
c) differential diagnosis of MRI findings.
d) expected clinical course.
Content organization: ALL is a common paediatric malignancy and a
common cause of non-traumatic paediatric mortality. Methotrexate
(MTX) is one of the key therapeutic agents utilised for treatment of
these patients.
MTX is well-known to be neurotoxic with/without associated radi-
ation therapy.
Neurotoxicity related to MTX administration may be manifest clinically
in the acute/subacute period as seizures, confusion and/or focal neuro-
logic deficits similar to other pathologic processes that these patients
are at risk for developing including stroke, opportunistic infection,
hemorrhage, venous sinus thrombosis and/or spread of neoplasm.
MRI is often performed in these patients to assess for abnormality.
While the majority of MR imaging sequences are usually normal in
patients with MTX-related neurotoxicity, supratentorial white matter
diffusion MR findings have been identified in an often reversible pat-
tern that appears to correlate with symptomatology.
Examples of children with reversible toxic leukoencephalopathy re-
lated to MTX administration will be reviewed. Proposed underlying
pathophysiologic mechanisms for the observed MRI findings will also
be reviewed.Conclusion: Leukoencephalopathy in ALL patients following IT MTX
administration should not be confused with other more ominous
pathologic processes that can also effect these patients. Interpreters
of paediatric neuroimaging studies should be aware of these MR
findings and their implications.
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Learning objectives: To demonstrate reporting errors, where normal
anatomy or variants have been described as pathology.
Content organisation: Computed tomography (CT) is the mainstay
of oncology diagnosis and follow up. With increasing number in reli-
ance of CT studies, the aim of this pictorial review is to highlight
common and uncommon pitfalls that occur during reporting second-
ary to normal variants and/or technical artefacts.
We aim to present organ specific examples and how to identify and
avoid unnecessary further investigations or under/over calling. These
would include: Lung Pleura
 Vascular structures.
 Solid abdominal organs.
 Peritoneum and soft tissue.
It is inevitable that there will be occasions when errors are made.
However some errors may drastically alter a patient’s management
plan and these individuals may be over or under treated.
Conclusions: With increased reliance on CT for oncological diagnosis
and follow up it is imperative to that errors in reporting are mini-
mised. It is however impossible to avoid all errors. Hence, we hope
this pictorial review will raise ones’ awareness on some of the areas
that may be prone to discrepancy in order to reduce unnecessary er-
rors in oncological reports.
P23
Imaging of perineural extension in head and neck tumours
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Learning objective: To present anatomical and patho-physiological
perspective of “Perineural extension” in Head and Neck Tumours, its
clinical implications and highlight the role of imaging through com-
prehensive pictorial essay of representative cases.
Content organisation: Nerves provide easy conduit for spread of
malignant cells in head and neck cancers. This involvement of
nerves, known as “Perineural extension”, is often clinically occult.
However, its presence up grades the tumour staging, alters treat-
ment planning and portends poorer prognosis. Imaging plays piv-
otal role in the assessment and precise delineation of perineural
extension.
We will review the:
 Importance of perineural extension in surgical treatment and
radiotherapy planning.
 Clinical presentation of perineural extension.
 Anatomy of cranial nerve distribution and inter-neural connec-
tions in head and neck region. Patho-physiological mechanism
of nerve involvement in cancer.
Cancer Imaging 2016, 16(Suppl 1):28 Page 31 of 34We will discuss the:
 Imaging planning and protocols for optimal detection of
perineural extension.
 Imaging features on CT, MRI and PET scan in perineural
extension. We will present the:
 Pictorial examples of spectrum of representative cases of
perineural extension.
 Differentia diagnosis and imaging pitfalls in perineural
extension.
Conclusion: Perineural extension in head and neck cancer influences
the prognosis. It has important implications on the surgical and radi-
ation treatment planning. Knowledge of pattern of perineural exten-
sion and the imaging features is essential for proper multidisciplinary
management of patients with head and neck and tumours.
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Learning objectives: Provide an overview of molecular classification
of breast cancer. To review the imaging features of the individual
subtypes of breast cancer based on recent studies.
Content organisation: Breast carcinoma is the most common malig-
nancy affecting women in the United States. Traditionally breast can-
cer is classified based on the morphologic features. In addition
predictive biologic markers including estrogen, progesterone recep-
tors, Her-2/neu receptor status and Ki-67 can be used to subclassify
breast cancer into following intrinsic subtype:1. Luminal A 2. Luminal
B 3. Her-2/neu or ERBB2 4. Basal.
Several recent studies have evaluated MRI features associated with
different intrinsic subtype of breast cancers. For example, ERBB2 and
luminal B subtypes have been noted to have increased incidence of
multicentric disease, multifocal disease, skin-nipple-periareolar in-
volvement, and axillary disease than luminal A. Preopertaive MRI in
Her-2/neu and luminal B, may thus be helpful to better define the
extent of disease for surgical planning and optimal local treatment.
Our presentation will be a pictorial essay demonstrating the MRI
features of some of the intrinsic subtypes of breast cancer using ex-
amples of the cases performed at our women’s imaging center.
Conclusions: Based on recent studies MRI features may be used to
predict molecular subtypes of breast cancer. However, currently data
is limited and further studies are needed to establish the role of pre-
operative MRI based on molecular subtypes.
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Learning objectives: Provide a pictorial review of imaging findings of
the common and uncommon emergencies seen specifically in pa-
tients with malignancy.
Content organisation: Cancers is a leading cause of morbidity and
mortality worldwide, with reported 14 million new cases and 8.2 mil-
lion cancer related deaths in year 2012. Newer improving cancer
therapies have resulted in overall increasing prevalence of cancer
despite significant cancer related mortality. Acute presentation of a
patient to ED may be a result of the primary disease, effect oftreatment or unrelated to the diagnosis of cancer. The oncological
emergencies are sub classified as metabolic, hematologic and struc-
tural conditions. Imaging plays a key role in identifying some of the
structural abnormalities such as cord compression or superior vena
cava syndrome or treatment complication.
We present a pictorial review of the common and uncommon
oncological emergencies seen in radiology department in emergency
setting. The focus will be on the conditions that have characteristic
imaging findings. The imaging case examples will include cases such
as superior vena cava syndrome, acute cord compression, massive
pulmonary embolism, chemotherapy related bowel perforation, intes-
tinal obstruction secondary to bowel mass and cerebral herniation
among others.
Conclusions: Oncological emergencies are uncommon cause of mor-
tality in cancer patients. However, with increasing cancer prevalence
radiologist should be familiar with the imaging features of the spe-
cific conditions in this subgroup of patient presenting to emergency
department.
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Learning objectives: To describe the MRI sequences used in the de-
tection of pancreatic neuroendocrine tumours (pNETs). To demon-
strate the typical MRI features of pNETs and highlight the atypical
features with reference to histologically proven cases.
Content organisation: PNETs may occur sporadically or in association
with syndromes such as multiple endocrine neoplasia and von Hip-
pel Lindau disease. Imaging detection can be challenging, particu-
larly when lesions are small. Early diagnosis is crucial to avoid
metastatic disease but may be difficult in cases of sporadic nonse-
creting tumours. We demonstrate a range of MRI images to illustrate
the variety of appearances that may be seen.
Conclusion: Being aware of the less common MRI appearances of
pNETs may encourage earlier consideration of a neuroendocrine
tumour, particularly in patients without a history of a familial
syndrome.
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Learning objectives: To review the imaging findings of gynaeco-
logical cancers in pregnancy; including the unusual as well as the
common presentations of malignancy in addition to conditions that
may mimic cancers.
Content organisation: Gynaecological cancers in pregnancy are
well recognised and cause great concern for the patient and her
healthcare professionals, as any treatment may also affect the de-
veloping foetus and reproductive tract. Management is influenced
by the tumour site and stage and nodal staging- all of which are
performed with non-ionising radiation. Ultrasound, especially TV
ultrasound, and MR are the most common imaging modalities.
We will present the most common gynaecological malignancies in
pregnancy, their typical findings; specific effects that drive growth in
pregnancy and typical appearances on radiological imaging. In
addition, we will also describe lesions that cause concern in preg-
nancy, may grow in size and have adverse appearances suggesting
malignancy but are actually benign on histology.
Cancer Imaging 2016, 16(Suppl 1):28 Page 32 of 34Imaging is all the more important in pregnancy as biochemical
markers such as Ca-125 and BHCG are already raised in pregnancy.
Conclusions: Gynaecological cancers in pregnancy cause great con-
cern and challenges to the Oncological Radiologist. The pertinent im-
aging findings are included in this pictorial review.
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Learning objectives: To review the recommendations for diagnosis
and investigation of suspected Paraneoplastic Neurological Syndromes
in the literature, and propose a guideline.
Content organisation: Paraneoplastic Neurological Syndromes (PNS)
almost always predates the detection of malignancy, and prompt
diagnosis increases likelihood of a favorable neurologic outcome.
However, true PNS are rare with even sub-specialty neurologists
often only seeing a handful of cases a year. Moreover, there are
many different PNS which span multiple neurological subspecialties,
each with different associated tumours.
We will discuss the different categories of PNS and their diagnostic
criteria.
We will also review the published recommendations on investiga-
tions for suspected PNS, and follow-up for definite PNS.
Lastly, we will propose a flowchart which summarises these recom-
mendations. This flowchart has been adopted by the Glasgow’s Insti-
tute of Neurological Sciences (the tertiary neurological centre for the
west of Scotland). It is intended to help make the published recom-
mendations more accessible to referring clinicians. In addition, it pro-
vides a valuable guide for reporting radiologists on what the
associated tumours are to help focus their reporting.
Conclusion: Clinicians requesting investigations for suspected PNS
should have an understanding of the different types of PNS, and de-
tail specific syndrome suspected in the imaging request. This will
provide a more focused imaging pathway. A simplified flowcharted
would aid achieving this for both the referring clinician and the
reporting radiologists.
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of prostate cancer after radical prostatectomy
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Learning objectives: To review the role of multi-parametric MRI
(mpMRI) in detection of suspected locally recurrent prostate cancer
when biochemical failure occurs after radical prostatectomy.
Content organisation: Rising prostate-specific antigen (PSA) levels
after radical prostatectomy may be an indicator of locally recurrent
prostate cancer. Recurrent disease occurs in up to 50 % of high risk
patients and 10 % of low risk patients within 15 years of surgery. Ris-
ing PSA levels, known as biochemical failure, can be due to local re-
currence and/or metastatic disease. Persistently raised PSA after
prostatectomy may be due to residual healthy glandular tissue in the
post-surgical bed.
I will review the current role of multi-parametric MRI (mpMRI) in the
detection of locally recurrent prostate cancer, including:
 Biochemical failure after radical prostatectomy.
 Indications and protocols for imaging.
 Implications of imaging findings for further management.I will discuss the imaging characteristics of post-prostatectomy
changes in the pelvis on mpMRI:
 Appearances of local tumour recurrence.
 Enhancement kinetics in differentiation of benign scarring from
tumour recurrence.
 Correlate mpMRI appearances of recurrent tumour with
histological findings.
Conclusions: Multi-parametric MRI is a useful tool in confirming the
diagnosis of locally recurrent prostate cancer after radical prostatec-
tomy in patients with biochemical failure. Combined imaging param-
eters assist in the differentiation of recurrent tumour from scarring
and residual healthy tissue. Imaging findings can be used to guide
further management such as salvage radiotherapy.
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Learning objectives: To demonstrate the use of the PI-RADS (Pros-
tate Imaging-Reporting and Data System) version 2 (v2) scoring sys-
tem for multi-parametric MRI (mpMRI) of the prostate, with imaging
examples correlated with histological findings.
Content organisation: mpMRI of the prostate gland is increasingly
being performed to assess the treatment naïve prostate gland prior
to performing biopsy in suspected prostate cancer. Advantages
include tumour detection and localisation of suspected clinically im-
portant lesions, facilitating individualised biopsy patterns for patients,
and providing an opportunity for staging without post-biopsy arte-
fact. MRI may also have a role in risk stratification potentially defer-
ring biopsy in some cases.
I will review the current PI-RADS v2 with imaging examples from our
own experience over the last 12 months in approximately 800
patients.
I will discuss the changes in scoring of lesions compared to PI-RADS
version 1(v1) with imaging examples.
I will present our local Prostate Cancer pathway and how mpMRI and
PI-RADSv2 has been incorporated into this.
Conclusions: PI-RADS provides a standardised approach to reporting
lesions detected on mpMRI of the prostate, with version 2 simplifying
the overall scoring system. Widespread incorporation into prostate
cancer pathways is needed to understand how best to apply mpMRI
findings to individual patients. Continuing experience will provide an
opportunity to investigate whether PI-RADS 3 indeterminate lesions
could be further characterised into those needing biopsy and those
that could be safely followed.
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Learning objectives:
1. To illustrate the patterns of hepatic parenchymal change/injury
following chemotherapy.
2. To differentiate benign changes in response to chemotherapy
from malignant disease.
3. To recognize response vs progression in patients undergoing
treatment with anti-angiogenesis agents.
Cancer Imaging 2016, 16(Suppl 1):28 Page 33 of 34Content organisation: Chemotherapy-induced hepatic toxicity is a
well recognised complication. Certain chemotherapy regimes in-
crease the likelihood of hepatic injury. The recognition of toxicity is
particularly important in patients being considered for liver resection.
MRI has a role in problem-solving when the CT appearances are
difficult to interpret.
We will present the more commonly encountered parenchymal
changes (steatosis, steatohepatitis, nodular regenerative hyperplasia,
sinusoidal obstructive syndrome), demonstrating the typical appear-
ances on CT and/or MRI.
The patterns of parenchymal change are different in patients who
have undergone long-term – and multiple – lines of chemotherapy –
these changes will also be demonstrated on CT and/or MRI.
Tumour response to newer anti-angiogenesis chemotherapy agents
differs from standard chemotherapy regimes – recognition of
‘pseudo-progression’ and the role of MRI in problem-solving will be
highlighted.
Conclusion: Chemotherapy- induced hepatic toxicity is a commonly
encountered complication, the features of which should be recog-
nised during standard follow-up reporting.
It is important to differentiate response from progression with newer
anti-angiogenesis chemotherapy agents.
MRI has a role in problem-solving when hepatic parenchymal and
response assessment is suboptimal on CT.
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Learning objectives: To identify normal, benign and metastatic
skeletal appearances on MRI.
To understand that processes, such as marrow conversion, reduce
sensitivity.
To identify complications of metastatic disease and extra-skeletal
findings.
Content organisation: Breast cancer commonly metastasizes to the
axial skeleton. Our local practice is to use a MRI marrow examination
using T1WI and STIR sagittal thoracic spine and coronal lumbar-pelvis
sequences.
We offer a pictorial review of key features that the radiologist needs
to know when reporting MRI marrow examinations for breast cancer
(re-)staging. This will include:
 Illustrations of normal appearances.
 Challenges posed by marrow conversion in reducing sensitivity
for detecting metastases.
 Review areas and localisers.
 Typical appearances of bone metastases: focal and diffuse
infiltration.
 Post treatment changes on MRI and the utility of the CT body
study to diagnose a healing response.
 Complications of malignant vertebral collapse and cord
compression.
 Benign processes that may be confused for metastatic disease,
such as insufficiency fractures, Modic changes, Paget’s disease
and benign lesions (eg Pitt’s pit).
 Extra-skeletal findings relevant to the assessment of
metastatic burden and/or breast cancer treatment include
adenopathy, pleural and pulmonary lesions, ascites,
hydronephrosis and pelvic lesions (eg endometrial
masses following tamoxifen).Conclusion: MRI is an excellent tool for assessing the skeleton for
metastases. Recognising benign and malignant appearances, appreci-
ating processes that limit interpretation, identifying potential compli-
cations and an awareness of extra-skeletal findings will allow for an
accurate report.
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Learning objectives:
 Perineural spread of disease is a rare yet potentially
devastating manifestation of lymphoma, that may occur in
isolation without other sites of nodal or extra nodal disease.
 CT, MR and PET-CT have an important role in the assessment
of perineural spread of disease.
Content organisation: Perineural spread of disease is most com-
monly encountered in the head and neck along branching cranial
nerves. However, in lymphoma, perineural involvement can be seen
almost anywhere in the body. It most often presents as a painful sen-
sorimotor neuropathy but presentation is variable and dependent
upon neural structures involved.
Any linear focus of abnormal FDG uptake especially in the distribu-
tions of major nerves without overt structural correlate raises suspi-
cion for perineurial involvement on FDG PET-CT. Retrospective
evaluation of previous imaging studies, such as contrast-enhanced
MR, can then performed in a “second look” evaluation.
Direct signs of perineural spread include increased prominence of
the nerve; with thickening and irregularity and avid enhancement.
Indirect signs include muscle weakness and atrophy suggesting de-
nervation. Indirect signs confirmed by CT are bony erosion, destruc-
tion and widening of exiting nerve foramina.
Conclusions: Perineural spread of disease in lymphoma is less com-
mon than the typical nodal masses and splenomegaly. Perineural
spread of disease has acute and chronic sequelae. It has a poor prog-
nosis and changes management of disease.
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Aim: To characterise the imaging findings of visually isoattenuating
pancreatic adenocarcinoma in MDCT, their secondary signs and their
correlation with MRI and US.
Content organisation: We reviewed MDTC performed in 85 patients
with a suspected pancreatic mass between September 2009 and May
2016. We obtained in all the cases multiplanar dynamic dual-phase
scan, and MIP reformatted images. Isoattenuating tumours were
found in 10 of them, all histologically confirmed at surgery (n = 7) or bi-
opsy (n = 3). These cases were diagnosed by MRI in 40 %, US in 30 %,
both modalities in 20 % and only CT in 10 %. Retrospectively we found
one or more subtle secondary signs on MDCT in all of them.
Summary: Isoattenuating pancreatic adenocarcinoma are a small but
meaningful percentage of pancreatic cancer (5,4 %).
Cancer Imaging 2016, 16(Suppl 1):28 Page 34 of 34They were histopathology more common moderately differentiated
(70 %) than well differentiated (10 %) and poorly differentiated (20 %).
Secondary signs, such as mass effect and/or convex contour abnor-
mality, loss of the normal acinar glandular pattern, dilated biliary and
pancreatic ducts, interrupted pancreatic duct, and atrophic distal
pancreatic parenchyma, are helpful in the diagnosis.
Although US may be a sensitive method in the detection of these tu-
mours in cases with adequate glandular visualisation; MRI can im-
prove the diagnosis providing better tissue characterisation,
especially with diffusion sequence and ADC map.
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Imaging of larynx cancer: when is CT, MRI or FDG PET/CT the best
test?
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Learning objectives: To review Computed Tomography (CT), Mag-
netic Resonance Imaging (MRI) and 18Fluorodeoxyglucose Positron
Emission Tomography/ Computed Tomography (PET/CT) in the diag-
nosis of larynx cancer with an emphasis on optimal imaging modality
to elucidate the features of larynx cancer pertinent to staging.Content organisation: CT is the most commonly performed im-
aging modality. It is fast, relatively inexpensive and widely
available. Tailored technique is required to ensure adequate
visualisation of larynx cancer and its relationship to associated
anatomical planes. Limitations include ability to detect small
and mucosal lesions and relative low sensitivity for cartilage
invasion.
MRI demonstrates superior soft tissue definition and accurate local
disease extent. Protocols need to be tailored for larynx cancer. MRI
enables superior visualisation of laryngeal cartilage invasion, pre and
para-glottic space invasion to confirm T3 and T4 disease with high
sensitivity and moderate specificity. Limitations include relative in-
creased cost, movement artefacts, longer acquisition times, patient
compatibility.
PET/CT main indication is detection of cervical adenopathy
(reported up to 20 % more accurate than CT or MRI), exclusion
of metastatic disease and synchronous primary. Limitations
include highest cost, physiological uptake and movement
artefacts.
We will discuss the strengths and weakness of each modality and im-
aging techniques to maximise larynx lesion conspicuity in CT, MRI
and PET/CT.
Conclusions: Accurate staging is essential in the diagnosis and
treatment of larynx cancer. A good understanding of the imaging
modalities, their purpose and optimisation enables accurate char-
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